Document:

timmooreemploymentagreem

     1.     EMPLOYMENT AGREEMENT   This EMPLOYMENT AGREEMENT (the “Agreement”) by and between Timothy Moore  (“Employee”) and Instil Bio Inc. (the “Company”) is effective as of September 6, 2022 (the  “Effective Date”).  The Company desires to employ Employee as its Chief Operating Officer (COO) and, in  connection therewith, to compensate Employee for Employee’s personal services to the  Company; and  Employee wishes to be employed by the Company as its Chief Operating Officer, and to  provide personal services to the Company in return for certain compensation.  Accordingly, in consideration of the mutual promises and covenants contained herein, the  parties agree to the following:  1. EMPLOYMENT BY THE COMPANY.  1.1 Position. Subject to the terms set forth herein, the Company agrees to  employ Employee in the position of Chief Operating Officer.  Employee hereby accepts such  employment. During the term of Employee’s employment with the Company, Employee will  devote Employee’s best efforts and substantially all of Employee’s business time and attention to  the business of the Company.  1.2 Duties. Employee will report to the Chief Executive Officer of the  Company (the “CEO”). Employee will perform such duties as are normally associated with  Employee’s position as Chief Operating Officer, as assigned from time to time by the CEO.  Employee shall perform Employee’s duties under this Agreement principally out of the Company’s  offices in the Greater Los Angeles area, or at such other location as mutually agreed; Employee  shall make such business trips to such places as may be necessary or advisable for the efficient  operations of the Company. Employee’s services shall include, though not limited to leading and  managing the Company’s manufacturing, Information Technology, Program Management, and  other critical company operations globally.  Employee shall also partner with finance, HR and  legal to establish a world-class manufacturing operation suited to the stage and development of the  Company.  1.3 Company Policies and Benefits. The employment relationship between  the parties shall also continue to be subject to the Company’s personnel policies and procedures  as they may be interpreted, adopted, revised or deleted from time to time in the Company’s sole  discretion, and Employee will continue to be eligible to participate on the same basis as similarly  situated employees in the Company’s benefit plans in effect from time to time during Employee’s  employment. All matters of eligibility for coverage or benefits under any benefit plan shall be  determined in accordance with the provisions of such plan. The Company reserves the right to  change, alter, or terminate any benefit plan in its sole discretion. Notwithstanding the foregoing,  in the event that the terms of this Agreement differ from or are in conflict with the Company’s  general employment policies or practices, this Agreement shall control.  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     2.    1.4 Indemnification. During employment and through at least the sixth  anniversary of Employee’s termination date, the Company shall maintain coverage for Employee  as a named insured on all directors’ and officers’ insurance maintained by the Company for the  benefit of its directors and officers on at least the same basis as all other covered individuals, as  well as indemnify Employee for claims to the fullest extent of applicable law and as set forth in  the Company’s Amended and Restated By-Laws and Amended and Restated Certificate of  Incorporation.  2. COMPENSATION.  2.1 Salary. Employee shall receive for Employee’s services to be rendered  hereunder an initial annualized base salary of $565,000, subject to annual review and adjustment  by the Company’s Board of Directors (the “Board”) (or any authorized committee thereof) in its  sole discretion, payable subject to standard federal and state payroll withholding requirements in  accordance with the Company’s standard payroll practices (“Base Salary”).  2.2 Target Bonus; Signing Bonus.   (a) While this Agreement is in effect, Employee shall be eligible for a  discretionary annual target bonus of up to 50% of Employee’s then-current Base Salary (“Target  Bonus”), determined by the Company in its sole discretion, and payable subject to standard federal  and state payroll withholding requirements. The Target Bonus will be paid in a single annual  installment paid no later than March 15 of the following year. Other than as set forth in Section  6.2(a)(ii), whether or not Employee earns any bonus will be dependent upon (a) Employee’s  continuous performance of services to the Company through the date any bonus is paid and (b) the  actual achievement of the applicable individual performance targets and goals by Employee during  the relevant bonus year as such targets and goals are reasonably established by the Board (or any  authorized committee thereof). The Board (or any authorized committee thereof) will determine  in its sole discretion the extent to which Employee has achieved the performance targets and goals  upon which the bonus is based and the amount of the bonus, which could be zero. Employee’s  eligibility for a bonus is subject to change in the discretion of the Board (or any authorized  committee thereof). For the 2022 calendar year, Employee shall be eligible for a bonus up to the  amount of the Target Bonus prorated for the months of Employee’s employment by the Company  in 2022.  (b) Employee shall be advanced, within forty-five (45) days of the  Effective Date, a signing and retention bonus in the amount of $100,000.00, less applicable  deductions and withholdings (the “Signing Bonus”), which will be earned in full on the eighteenth  (18) month anniversary of the Effective Date. If Employee resigns without Good Reason (as  defined below) or is terminated for Cause (as defined below) before the eighteenth (18) month  anniversary of the Effective Date, Employee shall be obligated to, and hereby agrees to, repay the  full after-tax amount of the Signing Bonus within thirty (30) days of the effective termination date.        DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     3.    2.3 Stock Options.   (a) Subject to approval by the Board (or any authorized committee  thereof), the Company shall grant Employee an option (the “Option”) to purchase 750,000 shares  of the Company’s common stock, with an exercise price equal to the fair market value of a share  of common stock as determined by the Board (or any authorized committee thereof) as of the date  of grant, pursuant to the terms of the Company’s 2021 Equity Incentive Plan (the “Plan”) and the  individual stock option grant notice and related agreements to be provided to Employee (the Plan  and such notice and related agreements, collectively, the “Equity Documents”). The Option will  vest subject to the terms and conditions of the Plan and Employee’s grant agreement, with 25% of  the shares subject to the Option vesting upon the first anniversary of the Effective Date and the  remaining 75% of the shares subject to the Option vesting over the subsequent 3-year period in  substantially equal monthly installments at a rate of 1/48th of the total shares subject to the Option  each month, subject to Employee’s continuous service as of each such vesting date.  2.4 Expense Reimbursement. The Company will reimburse Employee for  reasonable business expenses with proper documentation and in accordance with the Company’s  standard expense reimbursement policy. For the avoidance of doubt, to the extent that any  reimbursements payable to Employee are subject to the provisions of Section 409A of the Internal  Revenue Code of 1986, as amended (the “Code”): (a) any such reimbursements will be paid no  later than December 31 of the year following the year in which the expense was incurred, (b) the  amount of expenses reimbursed in one year will not affect the amount eligible for reimbursement  in any subsequent year, and (c) the right to reimbursement under this Agreement will not be subject  to liquidation or exchange for another benefit.   3. CONFIDENTIAL INFORMATION, INVENTIONS, NON-SOLICITATION AND NON-  COMPETITION OBLIGATIONS. As a condition of employment, Employee must execute and abide  by the Employee Confidential Information, Inventions, Non-Solicitation and Non-Competition  Agreement attached as Exhibit 1 (the “Confidential Information Agreement”), which may be  amended by the parties from time to time without regard to this Agreement. The Confidential  Information Agreement contains provisions that are intended by the parties to survive and do  survive termination or expiration of this Agreement.    4. OUTSIDE ACTIVITIES. Except as otherwise stated herein, during the term of  Employee’s employment with the Company, Employee will be required to faithfully serve the  Company and devote Employee’s full time and attention to the business and affairs of the  Company and the performance of Employee’s duties and responsibilities. Employee will not, while  employed by the Company, undertake or engage in any other employment, occupation or business  enterprise, including accepting any appointment to the board of directors of another company, that  would interfere or conflict, either directly or indirectly, with Employee’s responsibilities and the  performance of Employee’s duties hereunder except for (i) reasonable time devoted to personal  financial affairs or volunteer services for or on behalf of such religious, educational, nonprofit  and/or other charitable organizations as Employee may wish to serve, (ii) reasonable time devoted  to activities in the nonprofit and business communities consistent with Employee’s duties, and (iii)  such other activities as may be specifically approved by the Board (or any authorized committee  thereof). This restriction shall not, however, preclude the Employee (x) from owning less than one  percent (1%) of the total outstanding shares of a publicly traded company or (y) from employment  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     4.    or service in any capacity with Affiliates of the Company. As used in this Agreement, “Affiliates”  means entities under common management or control with the Company.  5. NO CONFLICT WITH EXISTING OBLIGATIONS. Employee reasonably believes that  Employee’s performance of all the terms of this Agreement and as an employee of the Company  does not and will not breach any agreement or obligation of any kind made prior to Employee’s  employment by the Company.  Employee has disclosed any existing agreements or obligations  Employee may have with prior employers or entities for which Employee has provided services.  Employee has not entered into, and Employee agrees that Employee will not enter into, any  agreement or obligation, either written or oral, in conflict herewith.  6. TERMINATION OF EMPLOYMENT. The parties acknowledge that Employee’s  employment relationship with the Company is at-will. Either Employee or the Company may  terminate the employment relationship at any time, with or without Cause. The provisions in this  Section govern the amount of compensation, if any, to be provided to Employee upon  termination  of employment and do not alter this at-will status.  6.1 Termination by the Company without Cause or Resignation by  Employee for Good Reason Not in Connection with a Change in Control.  (a) The Company shall have the right to terminate Employee’s  employment with the Company pursuant to this Section 6.1 at any time, in accordance with Section  6.7, without “Cause” (as defined in Section 6.3(b) below) by giving notice as described in Section  7.1 of this Agreement. A termination pursuant to Section 6.5 or 6.6 below is not a termination  without Cause for purposes of receiving the benefits described in this Section 6.1.  (b) If the Company terminates Employee’s employment at any time, not  in connection with a “Change in Control” (as that term is defined in the Plan), without Cause, or  Employee terminates Employee’s employment with the Company for “Good Reason” (as defined  in Section 6.1(g) below) and provided that such termination constitutes a “separation from service”  (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative  definition thereunder, a “Separation from Service”), then Employee shall be entitled to receive  the Accrued Obligations (defined in Section 6.1(d) below). If Employee complies with the  obligations in Section 6.1(c) below (including but not limited to the Release requirement),  Employee shall also be eligible to receive the following “Severance Benefits:”  (i) The Company will pay Employee an amount equal to  Employee’s then-current Base Salary for twelve (12) months, less all applicable withholdings and  deductions (“Severance”), paid in equal installments beginning on the Company’s first regularly  scheduled payroll date following the Release Effective Date (as defined in Section 6.1(c) below),  with the remaining installments occurring on the Company’s regularly scheduled payroll dates  thereafter.  (ii) Provided Employee timely elects continued coverage under  COBRA under the Company’s group health plans following such termination, the Company will  pay Employee’s COBRA premiums, to continue Employee’s health insurance coverage in effect  on the termination date until the earliest of: (1) twelve (12) months following the termination date;  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     5.    (2) the date when Employee becomes eligible for substantially equivalent health insurance  coverage in connection with new employment or self-employment; or (3) the date Employee  ceases to be eligible for COBRA continuation coverage for any reason, including plan termination  (such period from the termination date through the earlier of (1)-(3), (the “COBRA Payment  Period”). Notwithstanding the foregoing, if at any time the Company determines that its payment  of COBRA premiums on Employee’s behalf would result in a violation of applicable law  (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended  by the 2010 Health Care and Education Reconciliation Act), then in lieu of paying COBRA  premiums pursuant to this Section, the Company shall pay Employee on the last day of each  remaining month of the COBRA Payment Period a fully taxable cash payment equal to the  COBRA premium for such month, subject to applicable tax withholding, for the remainder of the  COBRA Payment Period. Nothing in this Agreement shall deprive Employee of Employee’s rights  under COBRA or ERISA for benefits under plans and policies arising under Employee’s  employment by the Company.  (iii)  Acceleration of the vesting of all outstanding unvested  time-based equity awards that are held by Employee as of the date of Employee’s Separation from  Service as to the number of shares that would have vested in accordance with the applicable  vesting schedule as if Employee had been in service for an additional six (6) months as of  Employee’s termination date (based upon months of service and not the occurrence of corporate  events or milestones).  (c) Employee will be paid all of the Accrued Obligations on the  Company’s first payroll date after Employee’s date of termination from employment or earlier if  required by law. Employee shall receive the Severance Benefits pursuant to Section 6.1(b) of this  Agreement if: (i) within the time frame provided by the Company, which shall be no later than the  60th day following the date of Employee’s Separation from Service, Employee has signed and  delivered to the Company a separation agreement containing an effective, general release of claims  in favor of the Company and its affiliates and representatives (with standard carve-outs for vested  benefits and equity, as well as indemnification), in the form presented by the Company (the  “Release”), which cannot be revoked in whole or in part by such date (the date that the Release  can no longer be revoked is referred to as the “Release Effective Date”); (ii) if Employee holds  any other positions with the Company or any Affiliate, including a position on the Board,  Employee resigns such position(s) with such resignation to be effective no later than the date of  Employee’s termination date (or such other date as requested by the Board (or any authorized  committee thereof)); (iii) Employee returns all Company property; (iv) Employee complies with  Employee’s post-termination obligations under this Agreement and the Confidential Information  Agreement; and (v) Employee complies with the terms of the Release, including without limitation  any non-disparagement and confidentiality provisions contained in the Release. To the extent that  any severance payments are deferred compensation under Section 409A of the Code, and are not  otherwise exempt from the application of Section 409A, then, if the period during which Employee  may consider and sign the Release spans two calendar years, the payment of Severance will not be  made or begin until the later calendar year.  (d) For purposes of this Agreement, “Accrued Obligations” are (i)  Employee’s accrued but unpaid salary through the date of termination, (ii) any unreimbursed  business expenses incurred by Employee payable in accordance with the Company’s standard  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     6.    expense reimbursement policies, (iii) benefits owed to Employee under any qualified retirement  plan or health and welfare benefit plan in which Employee was a participant in accordance with  applicable law and the provisions of such plan, and (iv) payment of any annual Bonus previously  approved by the Board (or any authorized committee thereof) in connection with a previously  completed calendar year but which has not yet been paid out.  (e) The Severance Benefits or Change in Control Severance Benefits  (defined below) provided to Employee pursuant to this Section 6.1 or Section 6.2 are in lieu of,  and not in addition to, any benefits to which Employee may otherwise be entitled under any  Company severance plan, policy or program.  (f) Any damages caused by the termination of Employee’s employment  without Cause would be difficult to ascertain; therefore, the Severance Benefits or Change in  Control Severance Benefits for which Employee is eligible pursuant to Section 6.1(b) or 6.2(a) in  exchange for the Release are agreed to by the parties as liquidated damages, to serve as full  compensation, and not as a penalty.  (g) For purposes of this Agreement, “Good Reason” shall mean the  occurrence of any of the following events without Employee’s consent: (i) a material reduction in  Employee’s Base Salary, which the parties agree is a one-time or aggregated reduction of at least  ten percent (10%) of Employee’s Base Salary (unless pursuant to a salary reduction program  applicable generally to the Company’s similarly situated employees); (ii) a material reduction in  Employee’s duties, authority, or responsibilities for the Company relative to Employee’s duties,  authority, or responsibilities in effect immediately prior to such reduction; (iii) a material breach  by the Company or any successor entity of any employment-related contract between the Company  and Employee; or (iv) the relocation of Employee’s principal place of employment, without  Employee’s consent, in a manner that lengthens Employee’s one-way commute distance by fifty  (50) or more miles from Employee’s then-current principal place of employment immediately  prior to such relocation; provided, however, that any such termination by Employee shall be  deemed for Good Reason pursuant to this definition only if: (1) Employee gives the Company  written notice of Employee’s intent to terminate for Good Reason within thirty (30) days following  Employee’s first learning of the condition(s) that Employee believes constitute(s) Good Reason,  which notice shall describe such condition(s); (2) the Company fails to remedy such condition(s)  within thirty (30) days following receipt of the written notice (the “Cure Period”); (3) the Company  has not, prior to receiving such notice from Employee, already informed Employee that  Employee’s employment with the Company is being terminated; and (4) Employee voluntarily  terminates Employee’s employment within thirty (30) days following the end of the Cure Period.  6.2 Termination by the Company without Cause or Resignation by  Employee for Good Reason in Connection with a Change in Control.  (a) In the event that the Company terminates Employee’s employment  without Cause or Employee resigns for Good Reason within three (3) months prior to or twelve  (12) months following the effective date of a Change in Control (“Change in Control Termination  Date”), then Employee shall be entitled to the Accrued Obligations and, subject to Employee’s  compliance with Section 6.1(b) and (c) above, including but not limited to the Release requirement  and Employee’s continued compliance with Employee’s obligations to the Company under  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     7.    Employee’s Confidential Information Agreement, then Employee will be eligible for the following  “Change in Control Severance Benefits”:  (i) Employee shall be eligible to receive the Severance Benefits  set forth in Sections 6.1(b)(i) and 6.1(b)(ii) under the terms and conditions described in Section  6.1;   (ii) The Company shall pay Employee an amount equal to  Employee’s full Target Bonus for the calendar year in which Employee’s termination occurs,  which shall be equivalent to 50% of Employee’s then-current Base Salary, payable subject to  standard federal and state payroll withholding requirements on the Company’s first regularly  scheduled payroll date following the Release Effective Date; and  (iii) Effective as of the later of Employee’s Change in Control  Termination Date or the effective date of the Change in Control, the vesting and exercisability of  all outstanding unvested equity awards that are held by Employee as of immediately prior to the  Change in Control Termination Date shall be accelerated (and lapse, in the case of reacquisition  or repurchase rights) in full.  6.3 Termination by the Company for Cause.  (a) The Company shall have the right to terminate Employee’s  employment with the Company at any time for Cause by giving notice as described in Section 6.7  of this Agreement.  (b) “Cause” for termination shall mean that the Company has  determined in its sole discretion that Employee has engaged in any of the following: (i) a material  breach of any covenant or condition under this Agreement or any other agreement between the  parties, after the expiration of 30 days without cure after written notice of such alleged breach to  the extent such breach is curable; (ii) any act constituting dishonesty, fraud, or immoral or  disreputable conduct which is reasonably likely to cause harm (including reputational harm) to the  Company; (iii) any conduct which constitutes a felony under applicable law; (iv) material violation  of any Company policy, after the expiration of 30 days without cure after written notice of such  violation to the extent such violation is curable; (v) refusal to follow or implement a clear, lawful  and reasonable directive of Company after the expiration of 30 days without cure after written  notice of such failure to the extent such failure is curable; (vi) gross negligence or incompetence  in the performance of Employee’s duties after the expiration of 30 days without cure after written  notice of such failure; or (vii) breach of fiduciary duty.  (c) In the event Employee’s employment is terminated at any time for  Cause, Employee will not receive the Severance Benefits, Change in Control Severance Benefits  or any other severance compensation or benefit, except that, consistent with the Company’s  standard payroll policies, the Company shall provide to Employee the Accrued Obligations.  6.4 Resignation by Employee (other than for Good Reason).  (a) Employee may resign from Employee’s employment with the  Company at any time by giving notice as described in Section 6.7.  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     8.    (b) In the event Employee resigns from Employee’s employment with  the Company (other than for Good Reason), Employee will not receive the Severance Benefits,  Change in Control Severance Benefits, or any other severance compensation or benefit, except  that, pursuant to the Company’s standard payroll policies, the Company shall provide to Employee  the Accrued Obligations.  6.5 Termination by Virtue of Death or Disability of Employee.  (a) In the event of Employee’s death while employed pursuant to this  Agreement, all obligations of the parties hereunder shall terminate immediately, and the Company  shall, pursuant to the Company’s standard payroll policies, provide to the Employee’s legal  representatives Employee’s Accrued Obligations.  (b) Subject to applicable state and federal law, the Company shall at all  times have the right, upon written notice to Employee, to terminate this Agreement based on the  Employee’s Disability (as defined below). Termination by the Company of the Employee’s  employment based on “Disability” shall mean termination because the Employee is unable due to  a physical or mental condition to perform the essential functions of Employee’s position with or  without reasonable accommodation for six (6) months in the aggregate during any twelve (12)  month period or based on the written certification of two licensed physicians (reasonably  acceptable to Employee or his guardian) of the likely continuation of such condition for such  period. This definition shall be interpreted and applied consistent with the Americans with  Disabilities Act, the Family and Medical Leave Act, and other applicable law. In the event  Employee’s employment is terminated based on the Employee’s Disability, Employee will not  receive the Severance Benefits, Change in Control Severance Benefits, or any other severance  compensation or benefit, except that, pursuant to the Company’s standard payroll policies, the  Company shall provide to Employee the Accrued Obligations.  6.6 Termination Due to Discontinuance of Business. Anything in this  Agreement to the contrary notwithstanding, in the event the Company’s business is discontinued  because it is rendered impracticable by substantial financial losses, lack of funding, legal decisions,  administrative rulings, declaration of war, dissolution, national or local economic depression or  crisis, or any reasons beyond the control of the Company, then this Agreement shall terminate as  of the day the Company determines to cease operation with the same force and effect as if such  day of the month were originally set as the termination date hereof. In the event this Agreement is  terminated pursuant to this Section 6.6, Employee will not receive any of the Severance Benefits,  Change in Control Severance Benefits, or any other compensation or benefits, except that, pursuant  to the Company’s standard payroll policies, the Company shall pay to Employee the Accrued  Obligations.  6.7 Notice; Effective Date of Termination.  (a) Termination of Employee’s employment pursuant to this Agreement  shall be effective on the earliest of:  (i) immediately after the Company gives notice to Employee of  Employee’s termination, with or without Cause, unless pursuant to Section 6.3(b)(i), 6.3(b)(iv),  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     9.    6.3(b)(v) or 6.3(b)(vi), in which case termination shall be effective thirty (30) days after notice if  not cured or unless the Company specifies a later date, in which case termination shall be effective  as of such later date;  (ii) immediately upon the Employee’s death;  (iii) ten (10) days after the Company gives notice to Employee of  Employee’s termination on account of Employee’s Disability, unless the Company specifies a later  date, in which case termination shall be effective as of such later date, provided that Employee has  not returned to the fulltime performance of Employee’s duties prior to such date;  (iv) ten (10) days after Employee gives written notice to the  Company of Employee’s resignation not for Good Reason, provided that the Company may set a  termination date at any time between the date of notice and the date of resignation, in which case  Employee’s resignation shall be effective as of such other date. Employee will receive  compensation through any required notice period; or  (v) for a termination for Good Reason, immediately upon  Employee’s full satisfaction of the requirements of Section 6.1(g).  (b) In the event notice of a termination under subsections (a)(i) and (iii)  above is given orally, at the other party’s request, the party giving notice must provide written  confirmation of such notice within five (5) business days of the request in compliance with the  requirement of Section 7.1 below. In the event of a termination for Cause, written confirmation  shall specify the subsection(s) of the definition of Cause relied on to support the decision to  terminate.  6.8 Cooperation with Company After Termination of Employment.  Following termination of Employee’s employment for any reason, Employee shall cooperate fully  with the Company in all matters relating to the winding up of Employee’s pending work including,  but not limited to, any litigation in which the Company is involved, and the orderly transfer of any  such pending work to such other employees as may be designated by the Company; provided,  however, that to the extent any post-employment transition of such work requires more than  twenty-five (25) hours of Employee’s time, Employee shall be compensated at a mutually  agreeable hourly rate. Further, Employee shall be reimbursed for any reasonable, preapproved  expenses incurred in connection herewith.  6.9 Section 409A.  (a) Notwithstanding anything to the contrary herein, the following  provisions apply to the extent severance benefits provided herein are subject to the Code and the  regulations and other guidance thereunder and any state law of similar effect (collectively, “Section  409A”). Severance shall not commence until the Employee has a “separation from service” (as  defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative  definition thereunder, a “separation from service”). Each installment of severance is a separate  “payment” for purposes of Treas. Reg. Section 1.409A-2(b)(2)(i), and the severance is intended to  satisfy the exemptions from application of Section 409A provided under Treasury Regulations  Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such exemptions are  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     10.    not available and Employee is, upon separation from service, a “specified employee” for purposes  of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences  under Section 409A, the timing of the severance payments shall be delayed until the earlier of (i)  six (6) months and one day after Employee’s separation from service, or (ii) Employee’s death.  The parties acknowledge that the exemptions from application of Section 409A to severance  benefits are fact specific, and any later amendment of this Agreement to alter the timing, amount  or conditions that will trigger payment of severance benefits may preclude the ability of severance  benefits provided under this Agreement to qualify for an exemption.  (b) It is intended that this Agreement shall comply with the  requirements of Section 409A, and any ambiguity contained herein shall be interpreted in such  manner as to avoid adverse personal tax consequences under Section 409A. Notwithstanding the  foregoing, the Company shall in no event be obligated to indemnify Employee for any taxes or  interest that may be assessed by the Internal Revenue Service pursuant to Section 409A of the  Code to payments made pursuant to this Agreement.  6.10 Certain Excise Taxes.  (a) Notwithstanding anything to the contrary in this Agreement, if any  payment or benefit Employee would receive from the Company or any other party whether in  connection with the provisions of this Agreement or otherwise (“Payment”) would (i) constitute a  “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this sentence,  be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such  Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the  largest portion of the Payment that would result in no portion of the Payment being subject to the  Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever  amount ((x) or (y)), after taking into account all applicable federal, state and local employment  taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate),  results in Employee’s receipt of the greatest economic benefit notwithstanding that all or some  portion of the Payment may be subject to the Excise Tax. If a Reduced Amount will give rise to  the greater after-tax benefit, the reduction in the Payments shall occur in the following order: (a)  reduction of cash payments; (b) cancellation of accelerated vesting of equity awards other than  stock options; (c) cancellation of accelerated vesting of stock options; and (d) reduction of other  benefits paid to Employee. Within any such category of payments and benefits (that is, (a), (b), (c)  or (d)), a reduction shall occur first with respect to amounts that are not “deferred compensation”  within the meaning of Section 409A and then with respect to amounts that are. In the event that  acceleration of compensation from Employee’s equity awards is to be reduced, such acceleration  of vesting shall be canceled, subject to the immediately preceding sentence, in the reverse order of  the date of grant.  (b) The independent registered public accounting firm engaged by the  Company for general audit purposes as of the day prior to the effective date of the event described  in Section 280G(b)(2)(A)(i) of the Code shall perform the foregoing calculations. If the  independent registered public accounting firm so engaged by the Company is serving as accountant  or auditor for the individual, entity or group effecting such event, the Company shall appoint a  nationally recognized independent registered public accounting firm to make the determinations  required hereunder. The Company shall bear all expenses with respect to the determinations by  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     11.    such independent registered public accounting firm required to be made hereunder. The  independent registered public accounting firm engaged to make the determinations hereunder shall  provide its calculations, together with detailed supporting documentation, to the Company and  Employee within thirty (30) calendar days after the date on which Employee’s right to a Payment  is triggered (if requested at that time by the Company or Employee) or at such other time as  reasonably requested by the Company or Employee. Any good-faith determinations of the  independent registered public accounting firm made hereunder shall be final, binding and  conclusive upon the Company and Employee.  7. GENERAL PROVISIONS.  7.1 Notices. Any notices required hereunder to be in writing shall be deemed  effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by electronic  mail or confirmed facsimile if sent during normal business hours of the recipient, and if not, then  on the next business day, (c) five (5) days after having been sent by registered or certified mail,  return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally  recognized overnight courier, specifying next-day delivery, with written verification of receipt. All  communications shall be sent to the Company at its primary office location and to Employee at  Employee’s address as listed on the Company payroll or Employee’s company-provided email  address, or at such other address as the Company or Employee may designate by ten (10) days’  advance written notice to the other.  7.2 Severability. Whenever possible, each provision of this Agreement will be  interpreted in such manner as to be effective and valid under applicable law, but if any provision  of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable  law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any  other provision or any other jurisdiction, but this Agreement will be reformed, construed and  enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been  contained herein.  7.3 Waiver. If either party should waive any breach of any provisions of this  Agreement, such party shall not thereby be deemed to have waived any preceding or succeeding  breach of the same or any other provision of this Agreement.  7.4 Complete Agreement. This Agreement and the Equity Documents  constitute the entire agreement between Employee and the Company with regard to the subject  matter hereof. This Agreement is the complete, final, and exclusive embodiment of the parties’  agreement with regard to this subject matter and supersedes any prior oral discussions or written  communications and agreements. This Agreement is entered into without reliance on any promise  or representation other than those expressly contained herein, and it cannot be modified or  amended except in writing signed by Employee and an authorized officer of the Company. The  parties have entered into a separate Confidential Information Agreement. Any such separate  agreement governs other aspects of the relationship between the parties, has or may have  provisions that survive termination of the Employee’s employment under this Agreement, may be  amended or superseded by the parties without regard to this agreement and is enforceable according  to its terms without regard to the enforcement provision of this Agreement.  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     12.    7.5 Counterparts. This Agreement may be executed in separate counterparts,  any one of which need not contain signatures of more than one party, but all of which taken  together will constitute one and the same Agreement.  7.6 Headings. The headings of the sections hereof are inserted for convenience  only and shall not be deemed to constitute a part hereof or to affect the meaning thereof.  7.7 Successors and Assigns. The Company shall assign this Agreement and its  rights and obligations hereunder in whole, but not in part, to any company or other entity with or  into which the Company may hereafter merge or consolidate or to which the Company may  transfer all or substantially all of its assets, if in any such case said company or other entity shall  by operation of law or expressly in writing assume all obligations of the Company hereunder as  fully as if it had been originally made a party hereto, but the Company may not otherwise assign  this Agreement or its rights and obligations hereunder. Employee may not assign or transfer this  Agreement, or any rights or obligations hereunder, other than to Employee’s estate upon  Employee’s death.  7.8 Choice of Law. All questions concerning the construction, validity and  interpretation of this Agreement will be governed by the law of the State of Delaware.  7.9 Resolution of Disputes. The parties recognize that litigation in federal or  state courts or before federal or state administrative agencies of disputes arising out of Employee’s  employment with the Company or out of this Agreement, or Employee’s termination of  employment or termination of this Agreement, may not be in the best interests of either Employee  or the Company, and may result in unnecessary costs, delays, complexities, and uncertainty. The  parties agree that any dispute between the parties arising out of or relating to the negotiation,  execution, performance or termination of this Agreement or Employee’s employment, including,  but not limited to, any claim arising out of this Agreement, claims under Title VII of the Civil  Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Age Discrimination in  Employment Act of 1967, the Americans with Disabilities Act of 1990, Section 1981 of the Civil  Rights Act of 1966, as amended, the Family and Medical Leave Act, the Employee Retirement  Income Security Act, and any similar federal, state or local law, statute, regulation, or any  common-law doctrine, whether that dispute arises during or after employment, shall be settled by  binding arbitration in accordance with the National Rules for the Resolution of Employment  Disputes of the American Arbitration Association; provided, however, that this dispute resolution  provision shall not apply to any separate agreements between the parties that do not themselves  specify arbitration as an exclusive remedy. The location for the arbitration shall be the Dallas,  Texas metropolitan area. Any award made by such panel shall be final, binding and conclusive on  the parties for all purposes, and judgment upon the award rendered by the arbitrators may be entered  in any court having jurisdiction thereof. The arbitrators’ fees and expenses and all administrative  fees and expenses associated with the filing of the arbitration shall be borne by the Company.  The  parties acknowledge and agree that their obligations to arbitrate under this Section survive the  termination of this Agreement and continue after the termination of the employment relationship  between Employee and the Company. The parties each further agree that the arbitration provisions  of this Agreement shall provide each party with its exclusive remedy, and each party expressly  waives any right it might have to seek redress in any other forum, except as otherwise expressly  provided in this Agreement. By electing arbitration as the means for final settlement of all  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

     13.    claims, the parties hereby waive their respective rights to, and agree not to, sue each other  in any action in a federal, state or local court with respect to such claims, but the parties may  seek to enforce in court an arbitration award rendered pursuant to this Agreement. The  parties specifically agree to waive their respective rights to a trial by jury, and further agree  that no demand, request or motion will be made for trial by jury.    DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

          IN WITNESS WHEREOF, the parties have executed this Employment Agreement on the  day and year first written above.    INSTIL BIO INC.  By:   Name: Bronson Crouch  Title: Chief Executive Officer           Employee:    By:   Name: Timothy Moore    DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

256228108 v8        EXHIBIT 1  EMPLOYEE CONFIDENTIAL INFORMATION, INVENTIONS, NON-SOLICITATION AND  NON-COMPETITION AGREEMENT  In consideration of my employment or continued employment by Instil Bio Inc., and its subsidiaries, parents,  affiliates, successors and assigns (together, “Company”), and the compensation now and later paid to me, as well as other  valuable consideration, I hereby enter into this Employee Confidential Information, Inventions, Non-Solicitation and Non- Competition Agreement (the “Agreement”) and agree as follows:  1. CONFIDENTIAL INFORMATION PROTECTIONS.  1.1 Recognition of Company’s Rights;  Nondisclosure.  I understand and acknowledge that my  employment by Company creates a relationship of  confidence and trust with respect to Company’s  Confidential Information (as defined below) and that  Company has a protectable interest therein.  At all times  during and after my employment, I will hold in confidence  and will not disclose, use, lecture upon or publish any of  Company’s Confidential Information, except as such  disclosure, use or publication may be required in  connection with my work for Company, or unless an  officer of Company expressly authorizes such disclosure in  writing.  I will obtain Company’s written approval before  publishing or submitting for publication any material  (written, verbal, or otherwise) that discloses and/or  incorporates any Confidential Information.  I hereby assign  to Instil Bio Inc. any rights I may have or acquire in such  Confidential Information and recognize that all  Confidential Information shall be the sole and exclusive  property of Instil Bio Inc. and its assigns. I will take all  reasonable precautions to prevent the inadvertent or  accidental disclosure of Confidential Information.   Notwithstanding the foregoing, pursuant to 18 U.S.C.  Section 1833(b), I shall not be held criminally or civilly  liable under any Federal or State trade secret law for the  disclosure of a trade secret that: (1) is made in confidence  to a Federal, State, or local government official, either  directly or indirectly, or to an attorney, and solely for the  purpose of reporting or investigating a suspected violation  of law; or (2) is made in a complaint or other document  filed in a lawsuit or other proceeding, if such filing is made  under seal.   1.2 Confidential Information.  The term  “Confidential Information” shall mean any and all  confidential knowledge, data or information of Company.  By way of illustration but not limitation, “Confidential  Information” includes (a) trade secrets, inventions, mask  works, ideas, processes, formulas, software in source or  object code versions, data, programs, other works of  authorship, know-how, improvements, discoveries,  developments, designs and techniques and any other  proprietary technology and all Intellectual Property Rights  (defined below) therein (collectively, “Inventions”);  (b) information regarding research, development, new  products, marketing and selling, business plans, budgets  and unpublished financial statements, licenses, prices and  costs, margins, discounts, credit terms, pricing and billing  policies, quoting procedures, methods of obtaining  business, forecasts, future plans and potential strategies,  financial projections and business strategies, operational  plans, financing and capital-raising plans, activities and  agreements, internal services and operational manuals,  methods of conducting Company business, suppliers and  supplier information, and purchasing; (c) information  regarding customers and potential customers of Company,  including customer lists, names, representatives, their  needs or desires with respect to the types of products or  services offered by Company, proposals, bids, contracts  and their contents and parties, the type and quantity of  products and services provided or sought to be provided to  customers and potential customers of Company and other  non-public information relating to customers and potential  Customers; (d) information regarding any of Company’s  business partners and their services, including names,  representatives, proposals, bids, contracts and their  contents and parties, the type and quantity of products and  services received by Company, and other nonpublic  information relating to business partners; (e) information  regarding personnel, employee lists, compensation, and   employee skills; and (f) any other nonpublic information  which a competitor of Company could use to the  competitive disadvantage of Company.  Notwithstanding  the foregoing, it is understood that, at all such times, I am  free to use information which was known to me prior to  employment with Company or which is generally known  in the trade or industry through no breach of this  Agreement or other act or omission by me.   Notwithstanding the foregoing or anything to the contrary  in this Agreement or any other agreement between  Company and me, nothing in this Agreement shall limit my  right to discuss my employment or report possible  violations of law or regulation with the Equal Employment  Opportunity Commission, the United States Department of  Labor, the National Labor Relations Board, the Securities  and Exchange Commission, or other federal government  agency or similar state or local agency or to discuss the  terms and conditions of my employment with others to the  extent expressly permitted by Section 7 of the National  Labor Relations Act or to the extent that such disclosure is  protected under the applicable provisions of law or  regulation, including but not limited to “whistleblower”  statutes or other similar provisions that protect such  disclosure.  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

   2.   1.3 Third Party Information.  I understand,  in addition, that Company has received and in the future  will receive from third parties their confidential and/or  proprietary knowledge, data or information (“Third Party  Information”) subject to a duty on Company’s part to  maintain the confidentiality of such information and to use  it only for certain limited purposes.  During my  employment and thereafter, I will hold Third Party  Information in confidence and will not disclose to anyone  (other than Company personnel who need to know such  information in connection with their work for Company) or  use, except in connection with my work for Company,  Third Party Information unless expressly authorized by an  officer of Company in writing.  1.4 Term of Nondisclosure Restrictions.  I  understand that Confidential Information and Third Party  Information is never to be used or disclosed by me, as  provided in this Section 1.  If a temporal limitation on my  obligation not to use or disclose such information is  required under applicable law, and the Agreement or its  restriction(s) cannot otherwise be enforced, I agree and  Company agrees that the two (2) year period after the date  my employment ends will be the temporal limitation  relevant to the contested restriction, provided, however,  that this sentence will not apply to trade secrets protected  without temporal limitation under applicable law.     1.5 No Improper Use of Information of  Prior Employers and Others.  During my employment by  Company, I will not improperly use or disclose  confidential information or trade secrets, if any, of any  former employer or any other person to whom I have an  obligation of confidentiality, and I will not bring onto the  premises of Company any unpublished documents or any  property belonging to any former employer or any other  person to whom I have an obligation of confidentiality  unless consented to in writing by that former employer or  person.     2. ASSIGNMENTS OF INVENTIONS.   2.1 Definitions.  As used in this Agreement,  the term “Intellectual Property Rights” means all trade  secrets, Copyrights, trademarks, mask work rights, patents  and other intellectual property rights recognized by the  laws of any jurisdiction or country; the term “Copyright”  means the exclusive legal right to reproduce, perform,  display, distribute and make derivative works of  a work of  authorship (as a literary, musical, or artistic work)  recognized by the laws of any jurisdiction or country; and   the term “Moral Rights” means all paternity, integrity,  disclosure, withdrawal, special and any other similar rights  recognized by the laws of any jurisdiction or country.  2.2 Excluded Inventions and Other  Inventions.  Attached hereto as Exhibit A is a list  describing all existing Inventions, if any, that may relate to  Company’s business or actual or demonstrably anticipated  research or development and that were made by me or  acquired by me prior to the commencement of my  employment with, and which are not to be assigned to,  Company (“Excluded Inventions”).  If no such list is  attached, I represent and agree that it is because I have no  rights in any existing Inventions that may relate to  Company’s business or actual or demonstrably anticipated  research or development.  For purposes of this Agreement,  “Other Inventions” means Inventions in which I have or  may have an interest, as of the commencement of my  employment, other than Company Inventions (defined  below) and Excluded Inventions.  I acknowledge and agree  that if I use any Excluded Inventions or any Other  Inventions in the scope of my employment, or if I include  any Excluded Inventions or Other Inventions in any  product or service of Company, or if my rights in any  Excluded Inventions or Other Inventions may block or  interfere with, or may otherwise be required for, the  exercise by Company of any rights assigned to Company  under this Agreement, I will immediately so notify  Company in writing.  Unless Company and I agree  otherwise in writing as to particular Excluded Inventions  or Other Inventions, I hereby grant to Company, in such  circumstances (whether or not I give Company notice as  required above), a non-exclusive, perpetual, transferable,  fullypaid and royalty-free, irrevocable and worldwide  license, with rights to sublicense through multiple levels of  sublicensees, to reproduce, make derivative works of,  distribute, publicly perform, and publicly display in any  form or medium, whether now known or later developed,  make, have made, use, sell, import, offer for sale, and  exercise any and all present or future rights in, such  Excluded Inventions and Other Inventions.  To the extent  that any third parties have rights in any such Other  Inventions, I hereby represent and warrant that such third  party or parties have validly and irrevocably granted to me  the right to grant the license stated above.     2.3 Assignment of Company Inventions.  Inventions assigned to Instil Bio Inc., or to a third party as  directed by Instil Bio Inc. pursuant to Section 2.6, are  referred to in this Agreement as “Company Inventions.”   Subject to Section 2.4 (Unassigned or Nonassignable  Inventions) and except for Excluded Inventions set forth in  Exhibit A and Other Inventions, I hereby assign to Instil  Bio Inc. all my right, title, and interest in and to any and all  Inventions (and all Intellectual Property Rights with  respect thereto) made, conceived, reduced to practice, or  learned by me, either alone or with others, during the  period of my employment by Company.  To the extent  required by applicable Copyright laws, I agree to assign in  the future (when any copyrightable Inventions are first  fixed in a tangible medium of expression) my Copyright  rights in and to such Inventions.  Any assignment of  Company Inventions (and all Intellectual Property Rights  with respect thereto) hereunder includes an assignment of  all Moral Rights.  To the extent such Moral Rights cannot  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

   3.   be assigned to Instil Bio Inc. and to the extent the following  is allowed by the laws in any country where Moral Rights  exist, I hereby unconditionally and irrevocably waive the  enforcement of such Moral Rights, and all claims and  causes of action of any kind against Company or related to  Company’s customers, with respect to such rights.  I  further acknowledge and agree that neither my successors- in-interest nor legal heirs retain any Moral Rights in any  Company Inventions (and any Intellectual Property Rights  with respect thereto).    2.4 Unassigned or Nonassignable  Inventions.  I recognize that this Agreement will not be  deemed to require assignment of any Invention that I  developed entirely on my own time without using  Company’s equipment, supplies, facilities, trade secrets or  Confidential Information, except for those Inventions that  either (i) relate to Company’s actual or anticipated  business, research or development or (ii) result from or are  connected with work performed by me for Company  (“Nonassignable Inventions”).  In addition, this  Agreement does not apply to any Invention which qualifies  fully for protection from assignment to Company under  any specifically applicable state law, regulation, rule or  public policy (“Specific Inventions Law”).    2.5 Obligation to Keep Company Informed.   During the period of my employment and for one (1) year  after termination of my employment, I will promptly and  fully disclose to Company in writing all Inventions  authored, conceived, or reduced to practice by me, either  alone or jointly with others.  In addition, I will promptly  disclose to Company all patent applications filed by me or  on my behalf within one (1) year after termination of  employment.  At the time of each such disclosure, I will  advise Company in writing of any Inventions that I believe  fully qualify for protection under the provisions of any  applicable Specific Inventions Law; and I will at that time  provide to Company in writing all evidence necessary to  substantiate that belief.  Company will keep in confidence  and will not use for any purpose or disclose to third parties  without my consent any Confidential Information  disclosed in writing to Company pursuant to this  Agreement relating to Inventions that qualify fully for  protection under a Specific Inventions Law.  If disclosure  of any Nonassignable Invention would cause me to violate  any confidentiality agreement, I understand that I am not to  disclose such Nonassignable Invention but am only to  disclose a cursory name for each such invention, a listing  of the party(ies) to whom it belongs and the fact that full  disclosure as to such Nonassignable Invention has not been  made for that reason.  I will preserve the confidentiality of  any Invention that does not fully qualify for protection  under a Specific Inventions Law.    2.6 Government or Third Party.  I agree that,  as directed by Company, I will assign to a third party,  including without limitation the United States, all my right,  title, and interest in and to any particular Company  Invention.    2.7 Ownership of Work Product.    (a) I acknowledge that all original works  of authorship which are made by me (solely or jointly with  others) within the scope of my employment and which are  protectable by Copyright are “works made for hire,”  pursuant to United States Copyright Act (17 U.S.C. Section  101).    (b) I agree that Instil Bio Inc. will  exclusively own all work product that is made by me  (solely or jointly with others) within the scope of my  employment, and I hereby irrevocably and unconditionally  assign to Instil Bio Inc. all right, title, and interest  worldwide in and to such work product. I understand and  agree that I have no right to publish on, submit for  publishing, or use for any publication any work product  protected by this Section, except as necessary to perform  services for Company.  2.8 Enforcement of Intellectual Property  Rights and Assistance.  I will assist Company in every  proper way to obtain, and from time to time enforce, United  States and foreign Intellectual Property Rights and Moral  Rights relating to Company Inventions in any and all  countries.  To that end I will execute, verify and deliver  such documents and perform such other acts (including  appearances as a witness) as Company may reasonably  request for use in applying for, obtaining, perfecting,  evidencing, sustaining and enforcing such Intellectual  Property Rights and the assignment thereof.  In addition, I  will execute, verify and deliver assignments of such  Intellectual Property Rights to Instil Bio Inc. or its  designee, including the United States or any third party  designated by Instil Bio Inc.  My obligation to assist  Company with respect to Intellectual Property Rights  relating to such Company Inventions in any and all  countries will continue beyond the termination of my  employment, but Company will compensate me at a  reasonable rate after my termination for the time actually  spent by me at Company’s request on such assistance. In  the event Company is unable for any reason, after  reasonable effort, to secure my signature on any document  needed in connection with the actions specified in this  paragraph, I hereby irrevocably designate and appoint  Company and its duly authorized officers and agents as my  agent and attorney in fact, which appointment is coupled  with an interest, to act for and in my behalf to execute,  verify and file any such documents and to do all other  lawfully permitted acts to further the purposes of the  preceding paragraph with the same legal force and effect  as if executed by me.  I hereby waive and quitclaim to  Company any and all claims, of any nature whatsoever,  which I now or may hereafter have for infringement of any  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

   4.   Intellectual Property Rights assigned under this Agreement  to Instil Bio Inc.   2.9 Incorporation of Software Code.  I agree  that I will not incorporate into any Company software or  otherwise deliver to Company any software code licensed  under the GNU General Public License or Lesser General  Public License or any other license that, by its terms,  requires or conditions the use or distribution of such code  on the disclosure, licensing, or distribution of any source  code owned or licensed by Company except in strict  compliance with Company’s policies regarding the use of  such software.  3. RECORDS.  I agree to keep and maintain adequate  and current records (in the form of notes, sketches,  drawings and in any other form that is required by  Company) of all Confidential Information developed by  me and all Company Inventions made by me during the  period of my employment at Company, which records will  be available to and remain the sole property of Company at  all times.  4. DUTY OF LOYALTY DURING EMPLOYMENT.  I  agree that during the period of my employment by  Company I will not, without Company’s express written  consent, directly or indirectly engage in any employment  or business activity which is directly or indirectly  competitive with, or would otherwise conflict with, my  employment by Company.      5. NO SOLICITATION OF EMPLOYEES,  CONSULTANTS, CONTRACTORS, OR CUSTOMERS OR  POTENTIAL CUSTOMERS.    I agree that during the period  of my employment and for the one (1) year period after the  date my employment ends for any reason, including but not  limited to voluntary termination by me or involuntary  termination by Company, I will not, as an officer, director,  employee, consultant, owner, partner, or in any other  capacity, either directly or through others, except on behalf  of Company:  5.1 solicit, induce, encourage, or participate in  soliciting, inducing or encouraging any person known to  me to be an employee, consultant, or independent  contractor of Company to terminate his or her relationship  with Company, even if I did not initiate the discussion or  seek out the contact;  5.2 solicit, induce, encourage, or participate in  soliciting, inducing, or encouraging any person known to  me to be an employee, consultant, or independent  contractor of Company to terminate his or her relationship  with Company to render services to me or any other person  or entity that researches, develops, markets, sells, performs  or provides or is preparing to develop, market, sell, perform  or provide Conflicting Services (as defined in Section 6  below);  5.3 hire, employ, or engage in a business  venture with as partners or owners or other joint capacity,  or attempt to hire, employ, or engage in a business venture  as partners or owners or other joint capacity, with any  person then employed by Company or who has left the  employment of Company within the preceding three (3)  months to research, develop, market, sell, perform or  provide Conflicting Services;  5.4 solicit, induce or attempt to induce any  Customer or Potential Customer (as defined below) to  terminate, diminish, or materially alter in a manner harmful  to Company its relationship with Company;   5.5 solicit or assist in the solicitation of any  Customer or Potential Customer to induce or attempt to  induce such Customer or Potential Customer to purchase  or contract for any Conflicting Services; or  5.6 perform, provide or attempt to perform or  provide any Conflicting Services for a Customer or  Potential Customer.  The parties agree that for purposes of this Agreement, a  “Customer or Potential Customer” is any person or entity  who or which, at any time during the one (1) year period  prior to my contact with such person or entity as described  in Sections 5.4-5.6 above if such contact occurs during my  employment or, if such contact occurs following the  termination of my employment, during the one (1) year  period prior to the date my employment with Company  ends: (i) contracted for, was billed for, or received from  Company any product, service or process with which I  worked directly or indirectly during my employment by  Company or about which I acquired Confidential  Information; or (ii) was in contact with me or in contact  with any other employee, owner, or agent of Company, of  which contact I was or should have been aware, concerning  the sale or purchase of, or contract for, any product, service  or process with which I worked directly or indirectly  during my employment with Company or about which I  acquired Confidential Information; or (iii) was solicited by  Company in an effort in which I was involved or of which  I was aware.      6. NON-COMPETE PROVISION.  I agree that for the  one (1) year period after the date my employment ends for  any reason, including but not limited to voluntary  termination by me or involuntary termination by Company,  I will not, directly or indirectly, as an officer, director,  employee, consultant, owner, partner, or in any other  capacity solicit, perform, or provide, or attempt to perform  or provide, Conflicting Services anywhere in the Restricted  Territory (as defined below), nor will I assist another  person to solicit, perform or provide or attempt to perform  or provide Conflicting Services anywhere in the Restricted  Territory.    DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

   5.   The parties agree that for purposes of this Agreement,  “Conflicting Services” means any product, service, or  process or the research and development thereof, of any  person or organization other than Company that directly  competes with a product, service, or process, including the  research and development thereof, of Company with which  I worked directly or indirectly during my employment by  Company or about which I acquired Confidential  Information during my employment by Company.   The parties agree that for purposes of this Agreement,  “Restricted Territory” means the one hundred (100) mile  radius of any of the following locations: (i) any Company  business location at which I have worked on a regular or  occasional basis during the preceding year; (ii) my home if  I work from home on a regular or occasional basis; (iii) any  potential business location of Company under active  consideration by Company to which I have traveled in  connection with the consideration of that location; (iv) the  primary business location of a Customer or Potential  Customer; or (v) any business location of a Customer or  Potential Customer where representatives of the Customer  or Potential Customer with whom I have been in contact in  the preceding year are based.    7. REASONABLENESS OF RESTRICTIONS.  7.1 I agree that I have read this entire  Agreement and understand it.  I agree that this Agreement  does not prevent me from earning a living or pursuing my  career.  I agree that the restrictions contained in this  Agreement are reasonable, proper, and necessitated by  Company’s legitimate business interests.  I represent and  agree that I am entering into this Agreement freely and with  knowledge of its contents with the intent to be bound by  this Agreement and the restrictions contained in it.  7.2 In the event that a court finds this  Agreement, or any of its restrictions, to be ambiguous,  unenforceable, or invalid, I and Company agree that the  court will read the Agreement as a whole and interpret the  restriction(s) at issue to be enforceable and valid to the  maximum extent allowed by law.  7.3 If the court declines to enforce this  Agreement in the manner provided in subsection 7.2, I and  Company agree that this Agreement will be automatically  modified to provide Company with the maximum  protection of its business interests allowed by law, and I  agree to be bound by this Agreement as modified.  7.4 Furthermore, the parties agree that the  market for Company’s products is the entire United States.   If, however, after applying the provisions of subsections  7.2 and 7.3, a court still decides that this Agreement or any  of its restrictions is unenforceable for lack of reasonable  geographic limitation and the Agreement or restriction(s)  cannot otherwise be enforced, the parties hereby agree that  the fifty (50) mile radius from any location at which I  worked for Company on either a regular or occasional basis  during the one (1) year immediately preceding termination  of my employment with Company shall be the geographic  limitation relevant to the contested restriction.   8. NO CONFLICTING AGREEMENT OR  OBLIGATION.  I represent that my performance of all the  terms of this Agreement and as an employee of Company  does not and will not breach any agreement to keep in  confidence information acquired by me in confidence or in  trust prior to my employment by Company.  I have not  entered into, and I agree that I will not enter into, any  agreement either written or oral in conflict with this  Agreement.  9. RETURN OF COMPANY PROPERTY.  When I leave  the employ of Company, I will deliver to Company any and  all drawings, notes, memoranda, specifications, devices,  formulas and documents, together with all copies thereof,  and any other material containing or disclosing any  Company Inventions, Third Party Information or  Confidential Information of Company.  I agree that I will  not copy, delete, or alter any information contained upon  my Company computer or Company equipment before I  return it to Company.  In addition, if I have used any  personal computer, server, or e-mail system to receive,  store, review, prepare or transmit any Company  information, including but not limited to, Confidential  Information, I agree to provide Company with a computer- useable copy of all such Confidential Information and then  permanently delete and expunge such Confidential  Information from those systems; and I agree to provide  Company access to my system as reasonably requested to  verify that the necessary copying and/or deletion is  completed.  I further agree that any property situated on  Company’s premises and owned by Company, including  disks and other storage media, filing cabinets or other work  areas, is subject to inspection by Company’s personnel at  any time with or without notice.  Prior to leaving, I will  cooperate with Company in attending an exit interview and  completing and signing Company’s termination statement  if required to do so by Company.  10. LEGAL AND EQUITABLE REMEDIES.    10.1 I agree that it may be impossible to assess  the damages caused by my violation of this Agreement or  any of its terms.  I agree that any threatened or actual  violation of this Agreement or any of its terms will  constitute immediate and irreparable injury to Company  and Company will have the right to enforce this Agreement  and any of its provisions by injunction, specific  performance or other equitable relief, without bond and  without prejudice to any other rights and remedies that  Company may have for a breach or threatened breach of  this Agreement.    DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

   6.   10.2 In the event Company enforces this  Agreement through a court order, I agree that the  restrictions of Sections 5 and/or 6 will remain in effect for  a period of up to twelve (12) months from the effective date  of the order enforcing the Agreement; provided, however,  that in no circumstances shall the total length of any  restriction exceed the original length of the restriction set  forth in Sections 5 or 6, as the case may be.   11. NOTICES.  Any notices required or permitted  under this Agreement will be given to Company at its  headquarters location at the time notice is given, labeled  “Attention Chief Executive Officer,” and to me at my  address as listed on Company payroll, or at such other  address as Company or I may designate by written notice  to the other.  Notice will be effective upon receipt or refusal  of delivery.  If delivered by certified or registered mail,  notice will be considered to have been given five (5)  business days after it was mailed, as evidenced by the  postmark.  If delivered by courier or express mail service,  notice will be considered to have been given on the  delivery date reflected by the courier or express mail  service receipt.  12. PUBLICATION OF THIS AGREEMENT TO  SUBSEQUENT EMPLOYER OR BUSINESS ASSOCIATES OF  EMPLOYEE.  12.1 If I am offered employment or the  opportunity to enter into any business venture as owner,  partner, consultant or other capacity while the restrictions  described in Sections 5 and/or 6 of this Agreement are in  effect I agree to inform my potential employer, partner, co- owner and/or others involved in managing the business  with which I have an opportunity to be associated of my  obligations under this Agreement and also agree to provide  such person or persons with a copy of this Agreement.   12.2 I agree to inform Company of all  employment and business ventures which I enter into while  the restrictions described in Sections 5 and/or 6 of this  Agreement are in effect, and I also authorize Company to  provide copies of this Agreement to my employer, partner,  co-owner and/or others involved in managing the business  with which I am employed or associated and to make such  persons aware of my obligations under this Agreement.    13. GENERAL PROVISIONS.   13.1 Governing Law; Consent to Personal  Jurisdiction.  This Agreement will be governed by and  construed according to the laws of the District of Columbia  as such laws are applied to agreements entered into and to  be performed entirely within District of Columbia between  District of Columbia residents.  I hereby expressly consent  to the personal jurisdiction and venue of the state and  federal courts for the county in which Company’s principal  place of business is located for any lawsuit filed there  against me by Company arising from or related to this  Agreement.    13.2 Severability.  In case any one or more of  the provisions, subsections, or sentences contained in this  Agreement will, for any reason, be held to be invalid,  illegal or unenforceable in any respect, such invalidity,  illegality or unenforceability will not affect the other  provisions of this Agreement, and this Agreement will be  construed as if such invalid, illegal or unenforceable  provision had never been contained in this Agreement.  If  moreover, any one or more of the provisions contained in  this Agreement will for any reason be held to be  excessively broad as to duration, geographical scope,  activity or subject, it will be construed by limiting and  reducing it, so as to be enforceable to the extent compatible  with the applicable law as it will then appear.  13.3 Successors and Assigns.  This Agreement  is for my benefit and the benefit of Company, its  successors, assigns, parent corporations, subsidiaries,  affiliates, and purchasers, and will be binding upon my  heirs, executors, administrators and other legal  representatives.    13.4 Survival.  The provisions of this  Agreement will survive the termination of my  employment, regardless of the reason, and the assignment  of this Agreement by Company to any successor in interest  or other assignee.  13.5 Employment At-Will.  I agree and  understand that nothing in this Agreement will change my  at-will employment status or confer any right with respect  to continuation of employment by Company, nor will it  interfere in any way with my right or Company’s right to  terminate my employment at any time, with or without  cause or advance notice.  13.6 Waiver.  No waiver by Company of any  breach of this Agreement will be a waiver of any preceding  or succeeding breach.  No waiver by Company of any right  under this Agreement will be construed as a waiver of any  other right.  Company will not be required to give notice to  enforce strict adherence to all terms of this Agreement.  13.7 Export.  I agree not to export, reexport, or  transfer, directly or indirectly, any U.S. technical data  acquired from Company or any products utilizing such  data, in violation of the United States export laws or  regulations.  13.8 Advice of Counsel.  I ACKNOWLEDGE  THAT, IN EXECUTING THIS AGREEMENT, I  HAVE HAD THE OPPORTUNITY TO SEEK THE  ADVICE OF INDEPENDENT LEGAL COUNSEL,  AND I HAVE READ AND UNDERSTOOD ALL OF  DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055A 

 

   7.   THE TERMS AND PROVISIONS OF THIS  AGREEMENT.  THIS AGREEMENT WILL NOT BE  CONSTRUED AGAINST ANY PARTY BY REASON  OF THE DRAFTING OR PREPARATION OF THIS  AGREEMENT.  13.9 Entire Agreement.  The obligations  pursuant to Sections 1 and 2 (except subsections 2.4 and  2.7(a)) of this Agreement will apply to any time during  which I was previously engaged, or am in the future  engaged, by Company as a consultant if no other agreement  governs nondisclosure and assignment of Inventions  during such period.  This Agreement is the final, complete  and exclusive agreement of the parties with respect to the  subject matter of this Agreement and supersedes and  merges all prior discussions between us; provided,  however, prior to the execution of this Agreement, if  Company and I were parties to any agreement regarding  the subject matter hereof, that agreement will be  superseded by this Agreement prospectively only.  No  modification of or amendment to this Agreement, or any  waiver of any rights under this Agreement, will be effective  unless in writing and signed by the party to be charged.   Any subsequent change or changes in my duties, salary or  compensation will not affect the validity or scope of this  Agreement.       This Agreement will be effective as of __________________________________.  I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS.  I HAVE COMPLETELY FILLED OUT  EXHIBIT A TO THIS AGREEMENT.         (Signature)     Timothy Moore  ACCEPTED AND AGREED TO:  INSTIL BIO INC.  By:                  Name: Bronson Crouch                 Title: Chief Executive Officer DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0 8/21/2022 099B E57 3E15 87E CB8 C2F AC3F055A 

 

    EXHIBIT A  LIST OF EXCLUDED INVENTIONS  1. Except as listed in Section 2 below, the following is a complete list of all inventions or improvements  relevant to the subject matter of my employment by Instil Bio Inc. that have been made or conceived or first reduced  to practice by me alone or jointly with others prior to my engagement by Instil Bio Inc.:   No inventions or improvements.   See below:  Title Date Identifying Number or Brief Description                          Additional sheets attached.  2. Due to a prior confidentiality agreement, I cannot complete the disclosure under Section 1 above with  respect to inventions or improvements generally listed below, the intellectual property rights and duty of  confidentiality with respect to which I owe to the following party(ies):    Invention or Improvement Party(ies)  Relationship    1.        2.        3.         Additional sheets attached.    DocuSign Envelope ID: 95198BE6-B28B-4F91-A60D-A0E117C6B7B0099B E57 3E15 87E CB8 C2F AC3F055AExhibit 10.1
​
Certain confidential information contained in this document, marked by brackets and *** asterisk, has been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K, because it (i) is not material and (ii) would be competitively harmful if publicly disclosed.
​
凯信生物医药(无锡)有限公司
CASI Biopharmaceuticals (Wuxi) Co., Ltd.
与
AND
深圳嘉道功程股权投资基金(有限合伙)
Shenzhen Jiadao Gongcheng Equity Investment Fund (Limited Partnership)
关于
ABOUT
转让合源生物科技(天津)有限公司股权
Transfer of Equity Interest in Juventas Biotechnology (Tianjin) Co., Ltd.
之
股权转让协议
Equity Transfer Agreement
​
本《股权转让协议》(”本协议”)于2022年9月22日(”签署日”)签订:
This Equity Transfer Agreement (this “Agreement”), dated September 22, 2022 (the “Execution Date”), is entered into by and between:
​
	1.
	凯信生物医药(无锡)有限公司,一家根据中国法律注册成立的有限责任公司,统一社会信用代码为91320206MA1Y9QKR89(”转让方”);

CASI Biopharmaceuticals (Wuxi) Co., Ltd., a limited liability company registered and incorporated under the laws of the PRC with uniform social credit code of 91320206MA1Y9QKR89 (the “Transferor”);
​
	2.
	深圳嘉道功程股权投资基金(有限合伙),一家根据中国法律注册成立的有限合伙企业,统一社会信用代码为91440300319612500C(”受让方”)。

Shenzhen Jiadao Gongcheng Equity Investment Fund (Limited Partnership), a limited partnership enterprise registered and incorporated under the laws of the PRC with its unified social credit code of 91440300319612500C (“Transferee”).
​
以上分别称为”一方”,合称为”双方”。
The above shall be referred to individually as a “Party” and collectively as the “Parties”.
​
鉴于:
​

1

Whereas,
​
	1.
	截至签署日,转让方持有对应合源生物科技(天津)有限公司(”标的公司”)注册资本[*****] 的股权。根据标的公司与转让方及其他相关方于2021年10月13日签署的《关于合源生物科技(天津)有限公司之股东协议》(”股东协议”),转让方就前述股权享有作为A+轮投资者(定义见股东协议)的权利。

As of the Execution Date, the Transferor holds [*****]  of the registered capital of Juventas Biotechnology (Tianjin) Co., Ltd. (the “Company”). In accordance with the Shareholders’ Agreement regarding Juventas Biotechnology (Tianjin) Co., Ltd., dated as of October 13, 2021, among the Company, Transferor, and other relevant parties (the “Shareholders’ Agreement”), the Transferor shall have the right as a Series A + Investor (as defined in the Shareholders’ Agreement) with respect to the aforesaid equity interests.
​
	2.
	受让方拟按照本协议的条款与条件受让转让方持有的对应标的公司注册资本[*****] 的股权,转让方拟按照本协议的条款与条件转让其持有的该等标的公司股权。

The Transferee intends to purchase the Transferor’s equity interests corresponding to [*****] of the registered capital of the Company, and the Transferor intends to transfer such equity interests in the Company, pursuant to the terms and subject to the conditions of this Agreement.
​
	3.
	标的公司与转让方的关联方(定义见下)CASI Pharmaceuticals, Inc.(”CASI US”)分别于2019年6月15日和2020年9月29日签署《Exclusive License Agreement》及《独家许可协议之补充协议》(合称”独家许可协议”)。本次股权转让(定义见下)完成后,转让方希望独家许可协议能够继续被严格履行。

The Company and CASI Pharmaceuticals, Inc., an Affiliate (defined below) of the Transferor, entered into the Exclusive License Agreement and the Supplementary Agreement to the Exclusive License Agreement (collectively the “Exclusive License Agreement”) on June 15, 2019 and September 29, 2020, respectively. It is the intention of the Transferor that the performance of the Exclusive License Agreement can be continuously secured after the completion of the Equity Transfer (defined below).
​
​

2

据此,双方达成本协议各项条款如下:
Now, therefore, the Parties agree as follows:
​
第一条本次股权转让
I.Equity Transfer
1.1本次股权转让
1.1Equity Transfer
​
	1.1.1
	转让方同意将其持有的截至签署日对应标的公司注册资本 [*****] 的股权(”目标股权”),按本协议的条款与条件以 [*****](”股权转让价款”)的对价转让给受让方,受让方同意按本协议的条款与条件受让目标股权(”本次股权转让”)。

	1.1.1
	The Transferor agrees to transfer to the Transferee its equity interests in the amount of [*****] of the registered capital of the Company as of the Execution Date (the “Target Equity”) for a consideration of [*****] (the “Equity Transfer Price”), subject to the terms and conditions of this Agreement, and the Transferee agrees to accept the transfer of the Target Equity subject to the terms and conditions of this Agreement (this “Equity Transfer”).

​
	1.1.2
	受限于本协议的约定,双方同意配合与本次股权转让相关的一切程序(包括但不限于在市场监督管理部门就本次股权转让办理的必要程序)。

	1.1.2
	Subject to the provisions herein, the Parties agree to cooperate in all procedures in connection with the Equity Transfer (including, without limitation, the procedures necessary for the Equity Transfer with the market supervision and administration authority).

​
第二条交割
II.Closing
2.1交割
2.1Closing
​
	2.1.1
	双方确认并同意,在本协议第四条规定的先决条件得以全部满足或受让方以书面形式予以豁免之日(”交割条件满足日”)后,受让方应分两期向转让方支付股权转让价款:

		(1)
	第一期:交割条件满足日起 [*****]内,受让方向转让方支付本次股权转让对价的[*****],即[*****] (大写:壹亿贰仟零肆拾叁万陆仟柒佰伍拾元整);

​

3

		(2)
	第二期:标的公司办理完毕标的股权的工商变更登记后[*****] 内,受让方向转让方支付本次股权转让对价的剩余[*****],即[*****] (大写:壹亿贰仟零肆拾叁万陆仟柒佰伍拾元整)。

转让方全额收到第一期股权转让价款之日为本次股权转让的首次付款日(”首次付款日”);转让方全额收到第二期股权转让价款之日为本次股权转让的交割日(”交割日”)。
​
	2.1.1
	The Parties acknowledge and agree that the Transferee shall pay the Equity Transfer Price to the Transferor in two tranches after the date on which all conditions precedent set forth in Article IV hereof are satisfied or waived by the Transferee in writing (the “Closing Conditions Satisfaction Date”):

​
		(1)
	The 1st Tranche: within [*****]  after the Closing Conditions Satisfaction Date, the Transferee shall pay [*****]  of the Equity Transfer Price, which is [*****];

​
		(2)
	The 2nd Tranche: within [*****]  after the completion of the Equity Transfer Registration, the Transferee shall pay the remaining [*****] of the Equity Transfer Price, which is  [*****];

The date on which the Transferor has received the first Tranche of the Equity Transfer Price in full shall be the date of first payment (the “First Payment Date”); the date on which the Transferor has received the second Tranche of the Equity Transfer Price in full shall be the closing date of the Transfer (the “Closing Date”).
​
	2.1.2
	双方确认并同意,转让方应在收到受让方支付的每期股权转让价款后的[*****] 内向受让方出具书面的收款通知,以证明受让方已完成该期股权转让价款支付义务。

	2.1.2
	The Parties acknowledge and agree that the Transferor shall issue a written receipt notice to the Transferee within [*****]   after the receipt of each tranche of the Equity Transfer Price paid by the Transferee to evidence that the Transferee has fulfilled its obligation to pay such tranche of the Equity Transfer Price.

​
2.2股东身份及股东权利
2.2Shareholders’ Status and Rights
​
	2.2.1
	自首次付款日起,受让方取得全部目标股权,并获得目标股权的全部权利、权属和权益,包括但不限于目标股权的所有权和任何与之相关的或

​

4

源于该所有权的权利和利益,同时承担目标股权对应的义务。
	2.2.1
	From the First Payment Date, the Transferee shall acquire all the Target Equity, as well as all rights, titles and interests in, to and under the Target Equity, including without limitation the ownership of the Target Equity and any rights and interests relating to or arising from such ownership, and shall assume the obligations corresponding to the Target Equity.

​
	2.2.2
	特别地,双方一致同意并确认,自首次付款日,受让方就目标股权享有作为A+轮投资者根据股东协议(或股东协议后续不时修订或者修改)享有相应的股东的权利。

	2.2.2
	In particular, the Parties unanimously agree and confirm that, upon the First Payment Date, the Transferee shall be entitled to the relevant shareholders’ rights as a Series A + Investor with respect to the Target Equity in accordance with the Shareholders’ Agreement, as amended or modified from time to time subsequently.

​
第三条陈述与保证和承诺
III.REPRESENTATIONS, WARRANTIES AND COVENANTS
3.1陈述与保证
3.1Representations and Warranties
​
	3.1.1
	转让方特此向受让方作出如下陈述与保证,并确认受让方对本协议的签署依赖于该等陈述与保证直至交割日(含交割日)在所有方面的真实、准确、完整和不具有误导性:

	3.1.1
	The Transferor hereby makes the following representations and warranties to the Transferee and acknowledges that the Transferee has entered into this Agreement in reliance on these representations and warranties being true, accurate, complete and not misleading in all respects as of the Closing Date (inclusive):

​
		(1)
	转让方系依照中国法律合法成立和有效存续的实体。

		(1)
	The Transferor is an entity duly organized and validly existing under the laws of China.

​
		(2)
	转让方根据适用法律具备民事权利能力和民事行为能力签署、交付和履行本协议项下与其相关事项;转让方已经就其签署、交付和履行本次股权转让项下与其相关事项取得所需的一切的授权、许可和批准。除本协议约定的各项变更手续(即在市场监督管理部门的变更登记/备案手续),转让方签署、交付和履行本协议并完成本次股权

​

5

转让项下与其相关事项无需获取任何第三方的同意、授权、许可或批准。本协议在经转让方签署后将构成对其合法、有效和具有约束力的义务,并可按照相应交易文件的条款对其强制执行。
		(2)
	The Transferor has the capacity for civil rights and conducts in accordance with applicable laws to execute, deliver and perform this Agreement. The Transferor has obtained all necessary authorizations, permits and approvals in connection with its execution, delivery and performance of the matters regarding the Transferor under the Equity Transfer. Except for the procedures for amendments as set forth in this Agreement (i.e. amendment registration/filing with the market supervision authority), the Transferor is not required to obtain any consent, authorization, permit or approval from any third party for the Transferor’s execution, delivery and performance of this Agreement or completion of the matters regarding the Equity Transfer. This Agreement will constitute a legal, valid and binding obligation of the Transferor, and will be enforceable against the Transferor in accordance with the provisions in the relevant transaction documents.

​
		(3)
	转让方签署、交付和履行本协议并完成本次股权转让,不会违反适用法律或任何政府指令,不会违反其章程或其他组织文件(如有),不会违反对其有约束力或适用的法院判决、裁定、仲裁庭裁决、行政决定、命令,不会违反转让方作为签约一方的任何文件、合同或协议,或对其或其资产具有约束力的任何文件、合同或协议,不会导致任何第三方向转让方提出任何权利请求。

		(3)
	The execution, delivery and performance of this Agreement and the completion of the Equity Transfer by the Transferor will not violate any applicable laws or any governmental orders, the articles of association or other organizational documents (if any), or any binding court judgments, rulings, arbitration tribunal awards, administrative decisions or orders binding upon or applicable to it, or any documents, contracts or agreements to which the Transferor is a party or any documents, contracts or agreements binding upon the Transferor or its assets, nor will it result in any third party to claim against the Transferor.

​
		(4)
	目标股权没有且不涉及任何国有资产,根据任何国有资产监管法律无需为完成本次股权转让而取得国有资产审批/备案手续、任何形式的国有资产评估程序,或进行任何国有资产产权交易所进场交易的相关程序。

​

6

		(4)
	The Target Equity does not involve any state-owned assets. Therefore, according to any law on the supervision and administration of state-owned assets, there is no need to obtain state-owned assets approval/filing procedures, any form of state-owned assets appraisal procedures, or relevant procedures to conduct any trading at any state-owned assets property exchange.

​
		(5)
	转让方是目标股权的合法持有人,其获得目标股权的对价均已经按时足额支付,且其持有的目标股权对应的注册资本已足额缴纳,转让方不存在迟延缴纳目标股权注册资本、虚假出资或抽逃出资的行为。转让方持有的目标股权上,不存在任何现有或潜在的争议、纠纷、诉讼、仲裁、索赔、强制执行或其他行政程序或法律程序。转让方持有的目标股权上不存在任何代持安排,亦不存在质押、抵押等担保权益或任何种类的权利负担,或任何其他第三方权利或权益。转让方对其持有的目标股权具有完全和排他的所有权和处分权,并具有依法转让其所持目标股权的权利。

		(5)
	The Transferor is the lawful holder of the Target Equity, and has fully paid the consideration for the Target Equity, and the registered capital corresponding to the Target Equity has been fully paid. The Transferor has not delayed payment of the registered capital for the Target Equity, committed false capital contribution or withdrawn capital contribution. There are no existing or potential disputes, disagreements, litigations, arbitrations, claims, enforcements or other administrative or legal proceedings in connection with the Target Equity. The Target Equity is not subject to any nominee holding arrangement, pledge, mortgage or other security interest or encumbrance of any kind, or any other third party right or interest. The Transferor has full and exclusive ownership and right to dispose of the Target Equity, and has the right to transfer the Equity Interest pursuant to law.

​
	3.1.2
	受让方特此向转让方作出如下陈述与保证,并确认转让方对本协议的签署依赖于该等陈述与保证直至交割日(含交割日)在所有方面的真实、准确、完整和不具有误导性:

	3.1.2
	The Transferee hereby makes the following representations and warranties to the Transferor and acknowledges that the Transferor has entered into this Agreement in reliance on these representations and warranties being true, accurate, complete

​

7

​
and not misleading in all respects as of the Closing Date (inclusive):
​
		(1)
	授权和有效性。受让方系依照中国法律合法成立和有效存续的实体。

		(1)
	Authority and Validity. The Transferee is an entity duly organized and validly existing under the laws of China.

​
		(2)
	受让方根据适用法律具备民事权利能力和民事行为能力签署、交付和履行本协议项下与其相关事项;受让方已经就其签署、交付和履行本次股权转让项下与其相关事项取得所需的一切的授权、许可和批准。除本协议约定的各项变更手续(即在市场监督管理部门的变更登记/备案手续),受让方签署、交付和履行本协议并完成本次股权转让项下与其相关事项无需获取任何第三方的同意、授权、许可或批准。本协议在经受让方签署后将构成对其合法、有效和具有约束力的义务,并可按照相应交易文件的条款对其强制执行。

		(2)
	The Transferee has the capacity for civil rights and conducts in accordance with applicable laws to execute, deliver and perform this Agreement. The Transferee has obtained all necessary authorizations, permits and approvals in connection with its execution, delivery and performance of the matters regarding the Transferee under the Equity Transfer. Except for the procedures for amendments as set forth in this Agreement (i.e. amendment registration/filing with the market supervision authority), the Transferee is not required to obtain any consent, authorization, permit or approval from any third party for the Transferee’s execution, delivery and performance of this Agreement or completion of the matters regarding the Equity Transfer. This Agreement will constitute a legal, valid and binding obligation of the Transferee, and will be enforceable against the Transferee in accordance with the provisions in the relevant transaction documents.

​
		(3)
	受让方签署、交付和履行本协议并完成本次股权转让,不会违反适用法律或任何政府指令,不会违反其章程或其他组织文件(如有),不会违反对其有约束力或适用的法院判决、裁定、仲裁庭裁决、行政决定、命令,不会违反受让方作为签约一方的任何文件、合同或协议,或对其或其资产具有约束力的任何文件、合同或协议,不会导致任何第三方向受让方提出任何权利请求。

		(3)
	The execution, delivery and performance of this Agreement and the completion of the Equity Transfer by the Transferee will not violate any applicable laws or any governmental orders, the articles of association or other organizational documents (if any), or any binding court judgments,

​

8

rulings, arbitration tribunal awards, administrative decisions or orders binding upon or applicable to it, or any documents, contracts or agreements to which the Transferee is a party or any documents, contracts or agreements binding upon the Transferee or its assets, nor will it result in any third party to claim against the Transferee.
​
		(4)
	本次股权转让系受让方的真实意思表示,受让方确认其用以购买目标股权的资金来源合法、合规,受让方具备履行本协议项下支付义务所需的财务能力。

		(4)
	The Equity Transfer is the expression of its true intentions. The Transferee confirms that the source of funds used to purchase the Target Equity is legal and compliant, and the Transferee has the financial capacity as required by the payment obligations hereunder.

​
3.2承诺
3.2Covenants
​
	3.2.1
	自签署日至交割日,除实施本协议项下的本次股权转让外,未经受让方事先书面同意,转让方不得转让、出售、质押或以其他任何方式处置目标股权,包括但不限于不得在其上设置任何权利负担;且转让方不得实施任何可能对目标股权或本协议或其他交易文件的履行有重大不利影响的行为;

	3.2.1
	From the Execution Date to the Closing Date, except for the Equity Transfer hereunder, without the prior written consent of the Transferee, Transferor shall not transfer, sell, pledge or otherwise dispose of the Target Equity, including without limitation not creating any encumbrance thereon; and the Transferor shall not take any action that may have any material adverse effect on the Target Equity or the performance of this Agreement or other Transaction Documents;

​
	3.2.2
	转让方应协助并配合标的公司及受让方就本次股权转让完成在市场监督管理部门的变更登记/备案手续,该等变更应体现本次股权转让安排以及相应的股东变更安排(”股权转让变更登记”)。转让方承诺,在其全额收到第一期股权转让价款(即[*****] )的前提下,其应尽商业合理努力协助并配合标的公司及受让方使得股权转让变更登记手续在下述日期孰早之日前完成:(1)转让方全额收到第一期股权转让价款(即[*****] )后第[*****] 届满之日;(2)2022年10月31日。转让方应在收到第一期股

​

9

​
权转让价款(即 [*****] )后的[*****]  内向公司及受让方提供股权转让变更登记中需转让方提供的文件和资料。
	3.2.2
	The Transferor shall assist and cooperate with the Company and the Transferee in completing the amendment registration/filing procedures with the relevant market supervision and administration authority; such change shall reflect the arrangement for the Equity Transfer and the arrangement for change of shareholders (the “Amendment Registration of Equity Transfer”). The Transferor covenants and undertakes that, in the event that it has received the first tranche of the Equity Transfer Price (i.e. [*****]) in full,  it shall make commercially reasonable efforts to assist and cooperate with the Company and the Transferee to ensure the Amendment Registration of Equity Transfer to be completed prior to the earlier of (1) the expiration of the [*****] after the date on which the Transferor has received the first tranche of the Equity Transfer Price (i.e. [*****]) in full; or (2) October 31, 2022. The Transferor shall, within [*****] after receiving the first tranche of the Equity Transfer Price (i.e. [*****]  in full), provide the Company and the Transferee with the documents and materials required for the Amendment Registration of Equity Transfer.

​
	3.2.3
	[*****]

​
第四条先决条件
IV.Conditions Precedent
受让方履行其在本协议项下的交割义务应以交割条件满足日或之前,下列条件全部得到满足、确认或被受让方以书面形式予以豁免为先决条件(”先决条件”):
The obligations of the Transferee to carry out the Closing hereunder shall be conditional upon the satisfaction, confirmation or written waiver by the Transferee of all of the following conditions on or prior to the date on which the Conditions Precedent are satisfied (the “Conditions Precedent”):
​
4.1双方同意并正式签署本协议;
	4.1
	Agreement and duly execution by the Parties of this Agreement;

​
​

10

​
4.2本次股权转让以及本次股权转让项下目标股权全部权利、权属和权益(包括目标股权享有A+轮投资者根据股东协议(或股东协议后续不时修订或者修改)享有相应的股东的权利)的一并转让取得标的公司股东会决议通过;
	4.2
	The Equity Transfer and the transfer of all rights, titles and interests in, to and under the Target Equity of the Equity Transfer (including the Target Equity shall be entitled to the relevant shareholders’ rights as a Series A + Investor with respect to the Target Equity in accordance with the Shareholders’ Agreement, as amended or modified from time to time subsequently) have been approved by the shareholders’ meeting of the Company;

​
	4.3
	转让方已经就其签署、交付和履行本次股权转让项下与其相关事项取得所需的一切的授权、许可和批准,包括但不限于转让方或关联方的股东会决议和/或董事会决议等。

	4.3
	The Transferor has obtained all necessary authorizations, permits and approvals in connection with its execution, delivery and performance of the matters regarding the Transferor under the Equity Transfer, including without limitation the shareholders resolutions and/or board resolutions of the Transferor or its Affiliates.

​
4.4转让方在本协议项下的陈述与保证自签署日至交割日持续保持是真实、完整、准确和不具有误导性的;转让方没有违反本协议约定的行为;
	4.4
	The representations and warranties of the Transferor under this Agreement remain true, complete, accurate and non-misleading as of the Execution Date to the Closing Date; the Transferor has not committed any act in violation of this Agreement;

​
4.5截至交割日,不存在限制、禁止本次股权转让的任何行动、程序,不存在任何尚未取得的与本次股权转让有关的许可、批准或第三方许可;
	4.5
	As of the Closing Date, there are no actions or procedures restricting or prohibiting the Equity Transfer, and there are no outstanding permits, approvals or third party permits in connection with the Equity Transfer;

​
​

11

​
4.6转让方向受让方出具书面付款通知,记载收取股权转让价款的转让方指定的银行账户;
	4.6
	The Transferor’s issuance of a written payment notice to the Transferee reflecting the payment of the Equity Transfer Price to the bank account designated by the Transferor;

​
4.7转让方向受让方出具书面交割通知,承诺本第四条规定的先决条件全部得到满足。
	4.7
	The Transferor’s issuance of a written closing notice to the Transferee undertaking the satisfaction of all the Conditions Precedent set forth in this Article IV.

​
第五条赔偿
V.INDEMNIFICATION
5.1赔偿
若一方或其关联方、董事、代表以及前述各主体的继承人和受让人(合称为”被赔偿方”)因下述事项遭受任何损失,另一方应对被赔偿方进行赔偿、保护并使其免受因下述原因而遭受或承担任何损失、损害、责任、成本或支出,包括但不限于合理的诉讼、仲裁费用和律师费,并使被赔偿方的权益恢复至该等事件未发生时的状态:
5.1INDEMNIFICATION
If a Party or its Affiliates, directors, representatives, successors and assignees (collectively, the “Indemnified Party”) suffers any losses arising from the following matters, the other Party shall indemnify, protect and hold the Indemnified Party harmless from and against any loss, damage, liability, cost or expense, including without limitation reasonable litigation or arbitration costs and attorneys’ fees, incurred or incurred by the Indemnified Party, and shall restore the Indemnified Party’s right and interest to that state if such events had not occurred, as a result of:
​
	5.1.1
	另一方在本协议项下中所作的任何陈述或保证不真实、不准确、不完整或存在误导性;

	5.1.1
	Any of the representations or warranties made by the other Party under this Agreement is untrue, inaccurate, incomplete or misleading;

​
​

12

​
	5.1.2
	另一方违反本协议规定的应由该方履行的任何承诺或义务。

	5.1.2
	The other Party is in breach of any covenant or obligation to be performed by such Party pursuant to this Agreement.

​
第六条终止
VI.Termination
	6.1
	合同解除的情形

	6.1
	Circumstances of Termination of the Contract

本协议可以通过下列方式解除:
This Agreement may be terminated in the following ways:
​
	6.1.1.
	本协议双方共同以书面协议解除并确定解除生效时间;

	6.1.1
	The Parties shall terminate this Agreement and determine the effective date of such termination by mutual written agreement;

​
	6.1.2
	受让方超过本协议约定的付款日期延迟付款超过 [*****],且经转让方催告后[*****] 仍未付款的;转让方有权发出书面通知单方解除本协议;

	6.1.2
	The Transferee is late for the payment described under this Agreement for more than [*****], and still fails to complete such payment within another  [*****] after being requested by the Transferor thereafter, the Transferor has the right, at its sole discretion, to terminate this Agreement by a written notice;

​
	6.1.3
	在受让方全额支付第一期股权转让价款(即 [*****])的前提下,股权转让变更登记未在本协议第3.2.2条约定的期限内完成且延期超过  [*****] ,经受让方催告后 [*****] 仍未完成的;受让方有权发出书面通知单方解除本协议。

	6.1.3
	In the event that the Transferor has received the first tranche of the Equity Transfer Price (i.e. [*****]) in full), if the Amendment Registration of Equity Transfer has not been completed within  [*****]  after the respective period as set forth in this Section 3.2.2, and has not been completed within another  [*****]  after being requested by the Transferee thereafter, the Transferee has the right, at its sole discretion, to terminate this Agreement by a written notice.

​
​

13

6.2合同解除的效力
	6.2
	Effect of Termination of Contract

​
	6.2.1.
	除非本协议另有约定,当本协议依上述之第6.1项任何一款解除后,本协议即无效力,但本协议第五条至第十条仍然有效。

	6.2.1
	Unless otherwise provided for in this Agreement, if this Agreement is terminated according to any of the provisions set forth in Section 6.1 above, this Agreement shall have no effect upon termination, except for Article V to Article X hereof.

​
	6.2.2.
	本协议解除后,受让方无需支付任何股权转让价款,若受让方已支付股权转让价款的,转让方应自本协议解除之日起 [*****] 内向受让方返还已支付的股权转让价款;如本协议解除之前股权转让变更登记已完成,受让方应促使标的公司于本协议解除之日起[*****] 内在相关市场监督管理部门完成相应的变更登记/备案手续,且受让方应促使该等变更确保转让方恢复为目标股权的登记持有人并享有股东协议下转让方原享有的全部股东权利。除本协议另有约定外,本协议解除后,本协议双方应本着公平、合理、诚实信用的原则在 [*****] 内或者双方另行确认的其他期限内尽最大努力恢复本协议签订前的状态。

	6.2.2
	Upon termination of this Agreement, the Transferee is not required to pay any Equity Transfer Price. If the Transferee has already paid the Equity Transfer Price, the Transferor shall refund the paid Equity Transfer Price to the Transferee within [*****]  after the termination of this Agreement; If the Amendment Registration of Equity Transfer is completed before the termination of this Agreement, the Transferee shall, within [*****]  after the termination, cause the Company to complete the amendment registration/filing procedures with the relevant market supervision and administration authority, which shall reflect that the Transferor reverts to the duly registered holder of the Target Equity and is entitled to all of its shareholder rights and benefits under the Shareholders’ Agreement. Unless otherwise provided for in this Agreement, after the termination of this Agreement, the Parties shall, based on the principles of fairness, reasonableness, honesty and good faith, make their best efforts to resume the status before the execution of this Agreement within [*****]  or other time limit as otherwise agreed by both Parties.

​
	6.2.3.
	本协议解除后,除本协议另有约定外,双方在本协议项下的权利和义务即告终止,但本协议的解除不影响任何一方在本协议项下获得赔偿或补

​

14

​
偿的权利。
	6.2.3
	Unless otherwise provided for in this Agreement, the rights and obligations of the Parties under this Agreement shall forthwith terminate upon the termination of this Agreement, provided that the termination of this Agreement shall not affect any Party’s rights to obtain indemnification or compensation under this Agreement.

​
第七条不可抗力
VII.Force Majeure
	7.1
	若由于地震、台风、洪水、火灾、流行病、战争、暴乱、敌对行动、公众动乱、罢工以及其他任何无法预见并且是受影响方无法防止亦无法避免的不可抗力事件(统称为”不可抗力”),而直接或间接致使本协议任何一方不能履行或不能完全履行本协议时,则受上述不可抗力影响的一方不对此不履行或部分履行承担责任,前提是该受影响方须立即毫不迟延地按照本协议约定的通知方式向另一方发出书面通知,并须在发出该书面通知后[*****] 内向另一方提供不可抗力事件的详情,解释其此种不能履行、部分不能履行或需要迟延履行的原因。

	7.1
	In the case of earthquakes, typhoons, floods, fires, flu, wars, riots, hostilities, public disturbances, strikes or any other events of force majeure that cannot be predicted and are unpreventable and unavoidable by the affected Party (collectively referred to as “Force Majeure”), which directly or indirectly causes the failure of either Party to perform or completely perform this Agreement, then the Party affected by such Force Majeure shall not be held liable for such non-performance or partial performance, provided that the affected Party shall immediately and without delay give the other Party written notice in accordance with the methods set forth herein, and shall provide details of the event of Force Majeure to the other Party within [*****]  after sending out such written notice, explaining the reasons for such failure of, partial or delay of performance.

​
	7.2
	若主张不可抗力的一方未能根据以上规定通知另一方并提供适当证明,其不得免于承担未能履行其在本协议项下义务的责任。受不可抗力影响的一方应作出合理的努力,以减低该不可抗力造成的后果,并在该不可抗力终止后尽快恢复履行所有有关义务。如受不可抗力影响的一方在因

​

15

​
不可抗力而暂免履行义务的理由消失后未有恢复履行有关义务,该方应就此向另一方承担责任。
	7.2
	If such Party claiming Force Majeure fails to notify the other Party and furnish it with proof pursuant to the above provision, such Party shall not be excused from non-performance of its obligations under this Agreement. The Party so affected by the event of Force Majeure shall use reasonable efforts to minimize the consequences of such Force Majeure and to promptly resume performance hereunder whenever the causes of such excuse are cured. Should the Party so affected by the event of Force Majeure fail to resume performance hereunder when the causes of such excuse are cured, such Party shall be liable to the other Party.

​
	7.3
	不可抗力发生时,双方应立即互相协商,以求达致公平解决方案,并须作出一切合理努力,尽量减低该不可抗力造成的后果。

	7.3
	In the event of Force Majeure, the Parties shall immediately consult with each other to find an equitable solution and shall use all reasonable endeavors to minimize the consequences of such Force Majeure.

​
第八条通知
VIII.Notices
	8.1
	本协议要求的或根据本协议做出的任何通知、请求、要求和其他通信往来应以书面形式送达有关方如附件一所示地址。

	8.1
	Any notice, request, demand and other correspondences required or given by this Agreement shall be made in writing and sent to the addresses of relevant Parties set forth in Appendix A.

​
	8.2
	该等通知或其他通信视为有效送达的日期按如下方式确定:(i) 面呈的通知在被通知人签收或拒收时视为送达;(ii) 可以邮寄方式进行的通知均应采用挂号快件或特快专递的方式进行,挂号快件应在投寄后第 [*****]  视为送达,特快专递应在被通知地址签收或拒收时视为送达;(iii) 经电子邮箱发送的通知自该邮件到达收件人邮箱系统之时视为已实际送达。

	8.2
	The dates on which such notices or other correspondences shall be deemed to have been effectively given shall be determined as follows: (i) notices delivered in person shall be deemed delivered upon receipt or refusal by the receiving Party; (ii) notices that may be sent by post shall be sent by registered mail or

​

16

​
express mail, and [*****]  after the registered mail is posted, or upon receipt or refusal at the address of the receiving Party, if delivered by express mail; (iii) notices sent by email shall be deemed effectively delivered upon delivery of such email into the email system of the recipients.
​
	8.3
	若任何一方的上述通讯地址或通知方式发生变化(”变动方”),变动方应当在该变更发生后的 [*****] 内通知其他方。变动方未按约定及时通知的,变动方应承担由此造成的损失。

	8.3
	If either Party changes the above mailing address or contact information (the “Changing Party”), it shall notify the other Party within [*****]  after the occurrence of such change. If the Changing Party fails to notify the other Party of the same in a timely manner, it shall bear the losses arising therefrom.

​
第九条保密
IX.Confidentiality
	9.1
	双方应就其签署本协议及其他交易文件的事实、本协议及其他交易文件的条款以及双方就签署和履行本协议及其他交易文件而交换的任何信息予以保密,不得向任何第三方披露前述信息。

	9.1
	The Parties shall maintain confidential the fact that the Parties have executed this Agreement and the other Transaction Documents, the terms hereof and thereof and any information exchanged by the Parties in connection with the execution and performance of this Agreement and the other Transaction Documents, and shall not disclose to any third party the aforementioned information.

​
	9.2
	上述限制不适用于:(i) 该信息在披露时已为公众所知悉;(ii) 为履行本协议项下交易之目的,一方向同意履行保密义务的其关联方、董事、股东、管理人员、员工、会计师、顾问、代表及代理人所披露;(iii) 一方按照对其有管辖权的政府部门的要求而披露,披露之前一方先以书面形式将披露的保密信息的确切性质通知其他方。如果可行,在作出上述披露前的合理时间内,披露方应与其他方就该披露进行协商,并就其他方合理要求尽可能对该披露寻求保密处理。

	9.2
	The above restrictions shall not apply to: (i) information which is already known to the public at the time of disclosure; (ii) information disclosed by a Party to its Affiliates, directors, shareholders, officers, employees, accountants, consultants,

​

17

​
representatives and agents who agree to comply with the obligations of confidentiality for the purpose of implementing the transactions contemplated hereby; (iii) information disclosed by a Party in accordance with the requirements of any competent governmental authority; provided, however, that prior to such disclosure, such Party shall have notified the other Parties in writing of the exact nature of the Confidential Information to be disclosed. If practicable, within the reasonable time before such disclosure, the disclosing Party shall consult with the other Parties regarding such disclosure and seek confidential treatment for such disclosure as much as possible upon the reasonable request of the other Parties.
​
	9.3
	不论本协议是否变更、解除或终止,本条均有法律效力。

	9.3
	This Article shall have legal effect irrespective of changes to, and rescission or termination of, this Agreement.

​
第十条其他条款
X.Miscellaneous Provisions
10.1生效日
本协议自双方正式签署(其中企业法人或其他非自然人实体须加盖公章)后于本协议文首所载日期起生效,构成对双方合法、有效及有约束力的权利及义务,可依照本协议的条款强制执行。
	10.1
	Effective Date

This Agreement shall become effective on the date first written above upon due execution by the Parties (corporate legal person or other non- natural person entity shall affix official seal). This Agreement shall constitute the legal, valid and binding rights and obligations of the Parties, enforceable in accordance with its terms.
​
10.2适用法律
本协议的签署、生效、履行、解释、终止以及争议的解决,均应适用中国法律。为本协议目的,本协议中提及的”中国法律”均指中华人民共和国法律,不包括香港特别行政区、澳门特别行政区和台湾地区法律。
	10.2
	Governing Law

The execution, effectiveness, performance, interpretation, termination of this Agreement and the resolution of disputes hereunder shall be governed by the
​

18

​
laws of China. For the purposes of this Agreement, the laws of China herein referred to shall mean the laws of the People’s Republic of China, and not include any laws of Hong Kong, Macao and Taiwan regions of China.
​
10.3争议解决
任何因本协议或其解释、违反、终止或有效性而引起的、或与之有关的争议、争论或申诉,均应提交至位于北京的中国国际经济贸易仲裁委员会,按照申请仲裁时该会现行有效的仲裁规则进行仲裁,仲裁地点在北京。仲裁裁决是终局的,对双方均有约束力。在根据本条仲裁程序进行期间,除仲裁事项之外,本协议应在所有方面保持全部效力。除仲裁事项所涉及的义务之外,双方应继续履行其在本协议项下的义务及行使其在本协议项下的权利。
	10.3
	Dispute Resolution

Any dispute, controversy or claim arising out of or relating to this Agreement, or the interpretation, breach, termination or validity hereof shall be submitted to China International Economic and Trade Arbitration Commission (“CIETAC”) in Beijing for arbitration in accordance with its arbitration rules in effect at the time of applying for arbitration. The arbitration shall be conducted in Beijing. The arbitration award shall be final and binding upon both Parties. During the course of arbitration proceedings under this Section, this Agreement shall remain in full force and effect in all respects except for the matter (s) under arbitration. Except for the obligations involved in the matter (s) under arbitration, the Parties shall continue to perform their obligations and exercise their rights under this Agreement.
​
10.4简版协议
双方同意为便于办理本次股权转让相关的政府程序,双方应善意协商另行签订与本协议项下事项有关的其他任何合同、协议或文件(包括但不限于根据市场监督管理部门的要求签署的简版股权转让协议及其他文件,如适用),但该等合同、协议或文件与本协议有任何矛盾或不一致之处,以本协议为准。
	10.4
	Short Form Agreement

The Parties agree that for the convenience of the government procedures relating to the Equity Transfer, the Parties shall negotiate in good faith any other contract, agreement or document relating to the matters hereunder (including,
​

19

​
without limitation, a short form equity transfer agreement and other documents, if applicable, executed as required by the market supervision and administration authority) to be separately entered into by the Both Parties. In the event of any contradiction or discrepancy between any of such contract, agreement or document and this Agreement, this Agreement shall prevail.
​
10.5整体协议
本协议是双方之间就本协议所涉及的事项达成的整体协议,取代本协议签署前所作的一切口头或书面的,明示或默示的协议、约定和陈述。
	10.5
	Entire Agreement

This Agreement shall constitute the entire agreement between the Parties with respect to the matters covered herein and shall supersede all oral or written, express or implied agreements, covenants and representations made prior to the execution of this Agreement.
​
10.6弃权
协议任何一方未行使或迟延行使本协议及其修改或补充协议所规定的任何权利或救济的行为,都不应构成或被视为弃权行为;任何单一或部分行使上述权利和救济的行为也不应妨碍对该权利和救济的进一步行使。
	10.6
	Waiver

No failure or delay on the part of either Party hereto to exercise any right or remedy provided for in this Agreement or any amendment or supplement hereto shall operate or be construed as a waiver of such right or remedy, nor shall any single or partial exercise of such right or remedy preclude any further exercise thereof or the exercise of any other right or remedy.
​
10.7可分割性
如果本协议中任何规定被判定为不合法、无效、或不具有可强制执行性,则双方同意该项规定应当在可行的最大限度内予以强制执行,以实现双方的意图,且本协议所有其他规定的有效性、合法性和可强制执行力均不受到任何损害。如果为了使双方的意图生效而有此必要的话,双方将以诚信协商修订本协议,以尽可能贴近上述意图且能够强制执行的文字来取代不可强制执行的文字。
	10.7
	Severability

If any provision of this Agreement shall be held to be illegal, invalid, or
​

20

​
unenforceable, the Parties agree that such provision shall be enforced, to the extent possible, so as to give effect to the intent of the Parties, and the validity, legality and enforceability of all other provisions of this Agreement shall not in any way be impaired. To the extent necessary to give effect to the intent of the Parties, the Parties shall negotiate in good faith to amend this Agreement by replacing the unenforceable provision with an enforceable provision that comes as close as possible to the intent of the Parties.
​
10.8税费承担
除非本协议另有规定,本次股权转让所涉及的各项税费按照中国法律的规定应由一方承担的,由该方自行承担并缴纳。受让方没有义务支付或代扣代缴转让方根据相关法律法规应为本协议项下的交易所需支付的税负。
办理股权转让变更登记所涉及的费用由标的公司承担并支付。任何一方要求就本次股权转让开展的评估、审计的,所发生的费用由其自行承担。
	10.8
	Taxes and Fees

Unless otherwise provided herein, all taxes involved in this Equity Transfer that should be borne by one Party according to the laws of China shall be borne and paid by the Party itself. The Transferee shall have no obligations to pay or withhold any tax of any nature that is required by the applicable Laws to be paid by the Transferor in connection with the transactions contemplated under this Agreement.
Any fees involved in handling the Amendment Registration of Equity Transfer shall be borne and paid by the Company. If either Party requests to conduct any evaluation or auditing on this Equity Transfer, the fees incurred thereof shall be borne by itself.
​
10.9转让和继承
本协议对双方当事人的继承人和受让人有效,上述继承人和受让人可享有本协议项下的权益并承担本协议项下的义务。未经另一方事先书面同意,任何一方均不得让与或转让其本协议项下的任何权利或义务。
	10.9
	Assignment and Succession

This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Parties and such successors and assigns may assume the obligations under this Agreement. Neither Party may assign or transfer any of
​

21

​
its rights or obligations under this Agreement without the prior written consent of the other Party.
​
10.10修改和补充
双方应以书面协议的方式对本协议进行修改和补充。经过双方签字的有关本协议的修改协议和补充协议是本协议的组成部分,具有与本协议同等的法律效力。
	10.10
	Amendments and Supplements

Any amendments and supplements to this Agreement shall be in writing. The amendment agreements and supplementary agreements that have been signed by the Parties and that relate to this Agreement shall be an integral part of this Agreement and shall have the same legal validity as this Agreement.
​
10.11附件
本协议的附件是本协议不可分割的组成部分,与本协议正文互为补充具有同等的法律效力,本协议附件与本协议冲突的,以本协议正文约定为准且须进行相应修改。
	10.11
	Appendix

The Appendix to this Agreement shall be an integral part of this Agreement and shall be complementary to the text of this Agreement and shall have the same legal validity. In the event of any conflict between the Appendix to this Agreement and this Agreement, the provisions of the text of this Agreement shall prevail and be modified accordingly.
​
10.12关联方
为本协议之目的,就任何特定的主体而言,其”关联方”系指任何直接或间接控制该主体,或直接或间接被该主体控制,或直接或间接与该主体共同受控制的任何其他主体。为免疑义,任何自然人的”关联方”还包括该自然人的近亲属,包括配偶、父母、祖父母、外祖父母、兄弟姐妹及其配偶、子女及其配偶、孙子女及其配偶、外孙子女及其配偶、配偶的父母、配偶的兄弟姐妹及其配偶、以该自然人及/或其近亲属作为受益人或全权信托对象的任何信托的受托人,以及由上述人员控制的任何主体也应视为该自然人的关联方。
	10.12
	Affiliates

For the purpose of this Agreement, an “Affiliate” of any specified Person means
​

22

​
any other Person that directly or indirectly Controls, is Controlled by, or is under common Control with, such specified Person. For the avoidance of doubt, the “Affiliate” of a natural person shall also include such natural person’s immediate family, including his or her spouse, parents, grandparents, siblings and their spouses, children and their spouses, grandchildren and their spouses, spouses’ parents, spouses’ brothers and sisters and their spouses, trustees of any trust of which such natural person and/or his or her immediate family is a beneficiary or discretionary object, and any Person Controlled by any of the aforesaid persons, shall also be deemed as an Affiliate of such natural person.
​
10.13语言和文本
本协议用中英文双语书就,如两种语言文本出现任何不一致的,应以中文文本为准。本协议一式四份,每份具有同等法律效力。
	10.13
	Language and Counterparts

This Agreement is written both in Chinese and English versions. In case of any discrepancy between the two language versions, the Chinese version shall prevail. This Agreement is made in four copies, and each copy shall have the same legal effect.
​
(以下无正文)
(The remainder of this page is intentionally left blank)
​
​

23

此证,本协议的每一方已促使其正式授权的代表于文首所载的日签订本协议,以昭信守。
IN WITNESS WHEREOF, each Party hereto has caused this Agreement to be executed by its duly authorized representative as of the date and year first above written.
​
凯信生物医药(无锡)有限公司(公章)
CASI Biopharmaceuticals (Wuxi) Co., Ltd. (Seal)
​
签署:/s/ Wei Zhang
______________________
Signature:
姓名:WEI ZHANG
Name: WEI ZHANG
职务:法定代表人
Title: Legal Representative
​
​

《凯信生物医药(无锡)有限公司与深圳嘉道功程股权投资基金(有限合伙)
关于转让合源生物科技(天津)有限公司股权之股权转让协议》签署页
Signature Page

​
此证,本协议的每一方已促使其正式授权的代表于文首所载的日期签订本协议,以昭信守。
IN WITNESS WHEREOF, each Party hereto has caused this Agreement to be executed by its duly authorized representative as of the date and year first above written.
​
深圳嘉道功程股权投资基金(有限合伙)(公章)
Shenzhen Jiadao Gongcheng Equity Investment Fund (Limited Partnership) (Seal)
​
签署:/s/ Kung Hung Ka
______________________
Signature:
姓名:
Name: Kung Hung Ka
职务:
Title: Authorized Representative
​
​

《凯信生物医药(无锡)有限公司与深圳嘉道功程股权投资基金(有限合伙)
关于转让合源生物科技(天津)有限公司股权之股权转让协议》签署页
Signature Page

附件一 通知信息
Appendix A Notice Information
​
	​
​

	​
[*****]
[*****]
[*****]
[*****]
[*****]
[*****]
​

	转让方
Transferor
	地址:中国北京市朝阳区 建国路81号华贸中心写字楼一座17层1701-1702
Address: 1701-1702 Tower 1,China Central Place, No. 81 Jianguo Street, Chaoyang district, Beijing, 100025, China
电话:[*****]
Telephone: [*****]
邮箱:[*****]
E-mail: [*****]
联系人:[*****]
Contact: [*****]

	受让方
Transferee
	地址:中国广州市天河区临江大道59号天銮广场A6栋3902室
Address: Room 3902, A6 Building, Tianluan Guangchang, No.59 Linjiang Avenue,  Tianhe district, Guangzhou,  China.
电话:[*****]
Telephone: [*****]
邮箱:[*****]
E-mail: [*****]
联系人:[*****]
Contact: [*****]

​

附件一Appendix A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]